Cat. No.: HY-13768

Topotecan

(Synonyms: SKF 104864A; NSC 609669)

38 Cited Publications

Customer Review

Based on 38 publication(s) in Google Scholar

Topotecan (SKF 104864A; NSC 609669) is an orally active and potent Topoisomerase I inhibitor. Topotecan induces cell cycle arrest in G0/G1 and S phases and promotes apoptosis. Topotecan shows anticancer activity.

For research use only. We do not sell to patients.

Purity: 98.04%
CAS No.: 123948-87-8
Formula: C₂₃H₂₃N₃O₅
Molecular Weight:421.45

Storage:

Powder -20°C, 3 years , 4°C, 2 years ; In solvent -80°C, 6 months , -20°C, 1 month

Topotecan Chemical Structure

CAS No.: 123948-87-8

Size

Price

Stock

Quantity

Sample (0.1mg)

In-stock

(In Japan)

Apply Now

Get Quote Ask For Quote & Lead Time Consult sales personnel for more information Check price and availability Get Quote Ask For Quote & Lead Time Consult sales personnel for more information Check price and availability

Bulk Inquiry

Amount: USD 0.00

* Please select Quantity before adding items.

Top Publications Citing

Use of MCE Products

Fluorescent Dye

Strong Fluorescence Signal / Multi-Disciplinary Applications / High Fluorescence Specificity

Biological Activity
- Description
- IC₅₀ & Target
- Cellular Effect
- In Vitro
- In Vivo
- Clinical Trial
Chemical Information
Publications (38)
Solvent & Solubility
- In Vitro
- In Vivo
Protocol
Purity & Documentation
References
Help & FAQs
Bioz

Biological Activity

Description

IC₅₀ & Target^[1]

Topoisomerase I

All Topoisomerase Isoforms :

Cellular Effect

Cell Line	Type	Value	Description	References
2008	IC₅₀	>500 nM Compound: 2	Antiproliferative activity against human 2008 cells assessed as inhibition of cell growth incubated for 72 hrs by SRB assay Antiproliferative activity against human 2008 cells assessed as inhibition of cell growth incubated for 72 hrs by SRB assay	[PMID: 35932565]
A2780	IC₅₀	22 μM Compound: Topotecan	Potentiation of growth inhibition of A2780 cells by compound alone in experiment 2 Potentiation of growth inhibition of A2780 cells by compound alone in experiment 2	[PMID: 11063605]
A2780	IC₅₀	22.6 μM Compound: Topotecan	Potentiation of growth inhibition of A2780 cells by compound alone in experiment 1 Potentiation of growth inhibition of A2780 cells by compound alone in experiment 1	[PMID: 11063605]
A2780	IC₅₀	7.8 μM Compound: Topotecan	Potentiation of growth inhibition of A2780 cells along with 10 uM NU1085 in experiment 1 Potentiation of growth inhibition of A2780 cells along with 10 uM NU1085 in experiment 1	[PMID: 11063605]
A2780	IC₅₀	8.7 μM Compound: Topotecan	Potentiation of growth inhibition of A2780 cells along with 10 uM NU1085 in experiment 2 Potentiation of growth inhibition of A2780 cells along with 10 uM NU1085 in experiment 2	[PMID: 11063605]
A2780	IC₅₀	0.058 μM Compound: Topotecan	In vitro cytotoxicity against A2780 (human ovarian cancer) In vitro cytotoxicity against A2780 (human ovarian cancer)	[PMID: 14552770]
A2780	IC₅₀	0.058 μM/L Compound: Topotecan	In vitro cytotoxicity against A2780 (human ovarian cancer) In vitro cytotoxicity against A2780 (human ovarian cancer)	[PMID: 14552770]
A2780	IC₅₀	1.1 μM Compound: Topotecan	Cytotoxicity against human A2780 cells after 96 hrs by MTT assay Cytotoxicity against human A2780 cells after 96 hrs by MTT assay	[PMID: 16792409]
A2780	IC₅₀	1.2 μM Compound: Topotecan	Cytotoxicity against human A2780 cells after 96 hrs by MTT assay Cytotoxicity against human A2780 cells after 96 hrs by MTT assay	[PMID: 17125236]
A2780	IC₅₀	3.35 μM Compound: 2, TPT	Cytotoxicity against human A2780 cells after 4 days by MTT assay Cytotoxicity against human A2780 cells after 4 days by MTT assay	[PMID: 18554906]
A2780	IC₅₀	0.006 μM Compound: 4	Cytotoxicity against human A2780 cells overexpressing alpha5beta3 integrin assessed as cell survival after 72 hrs by SRB assay Cytotoxicity against human A2780 cells overexpressing alpha5beta3 integrin assessed as cell survival after 72 hrs by SRB assay	[PMID: 22959246]
A2780	IC₅₀	33 nM Compound: Topotecan	Cytotoxicity against human A2780 cells after 72 hrs by MTT assay Cytotoxicity against human A2780 cells after 72 hrs by MTT assay	[PMID: 24900725]
A2780	IC₅₀	0.078 μM Compound: 2; TPT	Antiproliferative activity against human A2780 cells after 96 hrs by MTT assay Antiproliferative activity against human A2780 cells after 96 hrs by MTT assay	[PMID: 27871039]
A-375	IC₅₀	13 nM Compound: 7	Cytotoxicity against human A375 cells after 72 hrs by alamar blue assay Cytotoxicity against human A375 cells after 72 hrs by alamar blue assay	[PMID: 21341674]
A-427	IC₅₀	49 nM Compound: TPT	Antiproliferative activity measured against A427 human lung carcinoma Antiproliferative activity measured against A427 human lung carcinoma	[PMID: 9876111]
A498	IC₅₀	2 μM Compound: Topotecan	Inhibition of colony formation of human A498 cells after 2 weeks by crystal violet staining-based microscopic analysis Inhibition of colony formation of human A498 cells after 2 weeks by crystal violet staining-based microscopic analysis	[PMID: 29993250]
A549	IC₅₀	54 nM Compound: topotecan	In Vitro cytotoxicity against human lung cancer cell line (A549) In Vitro cytotoxicity against human lung cancer cell line (A549)	[PMID: 11334569]
A549	IC₅₀	24 nM Compound: Topotecan	Cytotoxic potentiation of Topotecan (TP) by the compound in human lung carcinoma A549 cell line Cytotoxic potentiation of Topotecan (TP) by the compound in human lung carcinoma A549 cell line	[PMID: 12408707]
A549	IC₅₀	0.087 μM Compound: Topotecan	In vitro cytotoxicity against A549 (human lung cancer) In vitro cytotoxicity against A549 (human lung cancer)	[PMID: 14552770]
A549	IC₅₀	0.087 μM/L Compound: Topotecan	In vitro cytotoxicity against A549 (human lung cancer) In vitro cytotoxicity against A549 (human lung cancer)	[PMID: 14552770]
A549	IC₅₀	0.0032 μM Compound: topotecan	Cytotoxicity against human A549 cells after 96 hrs by MTT assay Cytotoxicity against human A549 cells after 96 hrs by MTT assay	[PMID: 15165144]
A549	IC₅₀	24 nM Compound: Topotecan	In vitro cytotoxicity against human lung carcinoma A549 cells In vitro cytotoxicity against human lung carcinoma A549 cells	[PMID: 15481984]
A549	IC₅₀	3.3 μM Compound: Topotecan	Cytotoxicity against human A549 cells after 96 hrs by MTT assay Cytotoxicity against human A549 cells after 96 hrs by MTT assay	[PMID: 16792409]
A549	IC₅₀	3.5 μM Compound: Topotecan	Cytotoxicity against human A549 cells after 96 hrs by MTT assay Cytotoxicity against human A549 cells after 96 hrs by MTT assay	[PMID: 17125236]
A549	IC₅₀	3.1 μM Compound: Topotecan	Cytotoxicity against human A549 cells Cytotoxicity against human A549 cells	[PMID: 17279797]
A549	IC₅₀	0.005 μM Compound: topotecan, TPT	Antitumor activity against human A549 cells after 4 hrs by MTT assay Antitumor activity against human A549 cells after 4 hrs by MTT assay	[PMID: 18207748]
A549	IC₅₀	0.22 μM Compound: 2, TPT	Cytotoxicity against human A549 cells after 4 days by MTT assay Cytotoxicity against human A549 cells after 4 days by MTT assay	[PMID: 18554906]
A549	IC₅₀	0.48 μM Compound: Topotecan	Cytotoxicity against human A549 cells by SRB method Cytotoxicity against human A549 cells by SRB method	[PMID: 18986807]
A549	IC₅₀	0.36 μM Compound: 3	Antitumor activity against human A549/ATCC cells by SRB method Antitumor activity against human A549/ATCC cells by SRB method	[PMID: 19541483]
A549	GI₅₀	0.9 μM Compound: 3, TPT	Cytotoxicity against human A549 cells expressing wild type p53 after 48 hrs by SRB assay Cytotoxicity against human A549 cells expressing wild type p53 after 48 hrs by SRB assay	[PMID: 19715319]
A549	IC₅₀	1.9 μM Compound: 3, TPT	Cytotoxicity against human A549 cells expressing wild type p53 after 48 hrs by SRB assay Cytotoxicity against human A549 cells expressing wild type p53 after 48 hrs by SRB assay	[PMID: 19715319]
A549	GI₅₀	5.98 μM Compound: Topotecan	Antiproliferative activity against human A549 cells after 72 hrs by XTT assay Antiproliferative activity against human A549 cells after 72 hrs by XTT assay	[PMID: 19796956]
A549	IC₅₀	1.09 μM Compound: Topotecan	Cytotoxicity against human A549 cells after 3 days by MTT assay Cytotoxicity against human A549 cells after 3 days by MTT assay	[PMID: 20202723]
A549	IC₅₀	0.04 μM Compound: 2, Hycamtin	Cytotoxicity against human A549 cells after 72 hrs by MTT assay Cytotoxicity against human A549 cells after 72 hrs by MTT assay	[PMID: 20371183]
A549	IC₅₀	0.071 μM Compound: 2, TPT	Cytotoxicity against human A549 cells after 3 days Cytotoxicity against human A549 cells after 3 days	[PMID: 21333532]
A549	IC₅₀	3.16 μM Compound: TPT, Hycamptin	Cytotoxicity against human A549 cells after 3 days by MTT assay Cytotoxicity against human A549 cells after 3 days by MTT assay	[PMID: 21463912]
A549	GI₅₀	5.98 μM Compound: Topotecan	Growth inhibition of human A549 cells after 72 hrs by XTT assay Growth inhibition of human A549 cells after 72 hrs by XTT assay	[PMID: 22079254]
A549	GI₅₀	3.96 μM Compound: TPT	Cytotoxicity against human A549 cells incubated for 72 hrs by MTT assay Cytotoxicity against human A549 cells incubated for 72 hrs by MTT assay	[PMID: 22867019]
A549	IC₅₀	2.8 μM Compound: TPT	Antiproliferative activity against human A549 cells after 3 days by MTT assay Antiproliferative activity against human A549 cells after 3 days by MTT assay	[PMID: 23084702]
A549	IC₅₀	4.81 μM Compound: Top	Antiproliferative activity against human A549 cells after 72 hrs by XTT assay Antiproliferative activity against human A549 cells after 72 hrs by XTT assay	[PMID: 23237975]
A549	IC₅₀	4.81 μM Compound: Topotecan	Antiproliferative activity against human A549 cells after 3 days by XTT assay Antiproliferative activity against human A549 cells after 3 days by XTT assay	[PMID: 24727241]
A549	IC₅₀	354 nM Compound: Topotecan	Cytotoxicity against human A549 cells after 72 hrs by MTT assay Cytotoxicity against human A549 cells after 72 hrs by MTT assay	[PMID: 24900725]
A549	IC₅₀	0.0452 μM Compound: 2	Cytotoxicity against human A549 cells after 72 hrs sulforhodamine B colorimetric assay Cytotoxicity against human A549 cells after 72 hrs sulforhodamine B colorimetric assay	[PMID: 25008456]
A549	IC₅₀	0.045 μM Compound: 2	Cytotoxicity against human A549 cells after 72 hrs by SRB assay Cytotoxicity against human A549 cells after 72 hrs by SRB assay	[PMID: 25438769]
A549	IC₅₀	7.4 μM Compound: TPT	Cytotoxicity against human A549 cells after 72 hrs by MTT assay Cytotoxicity against human A549 cells after 72 hrs by MTT assay	[PMID: 26226379]
A549	IC₅₀	0.2 μM Compound: TPT	Antiproliferative activity against human A549 cells after 48 hrs by MTT assay Antiproliferative activity against human A549 cells after 48 hrs by MTT assay	[PMID: 26725027]
A549	IC₅₀	0.007 μM Compound: 2; TPT	Antiproliferative activity against human A549 cells after 96 hrs by MTT assay Antiproliferative activity against human A549 cells after 96 hrs by MTT assay	[PMID: 27871039]
A549	IC₅₀	112 nM Compound: 3	Cytotoxicity against human A549 cells after 72 hrs by sulforhodamine B assay Cytotoxicity against human A549 cells after 72 hrs by sulforhodamine B assay	[PMID: 28285912]
A549	IC₅₀	0.11 μM Compound: 3; TPT	Cytotoxicity against human A549 cells after 72 hrs by SRB assay Cytotoxicity against human A549 cells after 72 hrs by SRB assay	[PMID: 28789891]
A549	IC₅₀	112 nM Compound: 3	Cytotoxicity against human A549 cells after 72 hrs by SRB assay Cytotoxicity against human A549 cells after 72 hrs by SRB assay	[PMID: 28927790]
A549	IC₅₀	1.424 μM Compound: Topotecan	Cytotoxicity in human A549 cells assessed as reduction in cell viability incubated for 48 hrs by MTT assay Cytotoxicity in human A549 cells assessed as reduction in cell viability incubated for 48 hrs by MTT assay	[PMID: 30227711]
A549	IC₅₀	58.4 nM Compound: Topotecan	Cytotoxicity against human A549 cells assessed as growth inhibition measured after 72 hrs by MTT assay Cytotoxicity against human A549 cells assessed as growth inhibition measured after 72 hrs by MTT assay	[PMID: 31881457]
A549	IC₅₀	1.11 μM Compound: TPT	Antiproliferative activity against human A549 cells assessed as inhibition of cell growth incubated for 72 hrs by MTT assay Antiproliferative activity against human A549 cells assessed as inhibition of cell growth incubated for 72 hrs by MTT assay	[PMID: 34990980]
A549	IC₅₀	8.3 μM Compound: Topotecan	Antiproliferative activity against human A549 cells assessed as cell growth inhibition incubated for 8 hrs by CCK8 assay Antiproliferative activity against human A549 cells assessed as cell growth inhibition incubated for 8 hrs by CCK8 assay	[PMID: 35238576]
A549	IC₅₀	3.2 nM Compound: 5; TPT	Antiproliferative activity against human A549 cells assessed as reduction in cell viability measured for 48 hrs by CCK-8 assay Antiproliferative activity against human A549 cells assessed as reduction in cell viability measured for 48 hrs by CCK-8 assay	[PMID: 38421819]
ACHN	GI₅₀	0.04 μM Compound: Topotecan	In vitro anti-cancer activity against ACHN(Renal) human tumor cell line In vitro anti-cancer activity against ACHN(Renal) human tumor cell line	[PMID: 10397491]
ACHN	GI₅₀	0.04 μM Compound: Topotecan	Tested in vitro for cytotoxicity against human tumor cell line ACHN (renal). Tested in vitro for cytotoxicity against human tumor cell line ACHN (renal).	[PMID: 10714502]
AGS	GI₅₀	0.1 μM Compound: 3, TPT	Cytotoxicity against human AGS cells expressing wild type p53 after 48 hrs by SRB assay Cytotoxicity against human AGS cells expressing wild type p53 after 48 hrs by SRB assay	[PMID: 19715319]
AGS	IC₅₀	0.3 μM Compound: 3, TPT	Cytotoxicity against human AGS cells expressing wild type p53 after 48 hrs by SRB assay Cytotoxicity against human AGS cells expressing wild type p53 after 48 hrs by SRB assay	[PMID: 19715319]
Astrocyte	IC₅₀	0.16 μM Compound: Topotecan	Cytotoxicity against normal human astrocytes assessed as cell viability incubated for 72 hrs by WST-1 method Cytotoxicity against normal human astrocytes assessed as cell viability incubated for 72 hrs by WST-1 method	[PMID: 26355532]
Bel-7402	IC₅₀	0.078 μM Compound: Topotecan	In vitro cytotoxicity against Bel7402 (human liver cancer) In vitro cytotoxicity against Bel7402 (human liver cancer)	[PMID: 14552770]
Bel-7402	IC₅₀	0.078 μM/L Compound: Topotecan	In vitro cytotoxicity against Bel7402 (human liver cancer) In vitro cytotoxicity against Bel7402 (human liver cancer)	[PMID: 14552770]
Bel-7402	IC₅₀	0.0012 μM Compound: topotecan	Cytotoxicity against human Bel7402 cells after 96 hrs by MTT assay Cytotoxicity against human Bel7402 cells after 96 hrs by MTT assay	[PMID: 15165144]
Bel-7402	IC₅₀	3.98 μM Compound: Topotecan	Inhibitory concentration against human Bel-7402 liver cancer cell line Inhibitory concentration against human Bel-7402 liver cancer cell line	[PMID: 15808456]
Bel-7402	IC₅₀	1.2 μM Compound: Topotecan	Cytotoxicity against human Bel7402 cells after 96 hrs by MTT assay Cytotoxicity against human Bel7402 cells after 96 hrs by MTT assay	[PMID: 16792409]
Bel-7402	IC₅₀	1.4 μM Compound: Topotecan	Cytotoxicity against human Bel-7402 cells after 96 hrs by MTT assay Cytotoxicity against human Bel-7402 cells after 96 hrs by MTT assay	[PMID: 17125236]
Bel-7402	IC₅₀	1.4 μM Compound: Topotecan	Cytotoxicity against human Bel7402 cells Cytotoxicity against human Bel7402 cells	[PMID: 17279797]
Bel-7402	IC₅₀	3.13 μM Compound: 2, TPT	Cytotoxicity against human BEL-7402 cells after 4 days by MTT assay Cytotoxicity against human BEL-7402 cells after 4 days by MTT assay	[PMID: 18554906]
Bel-7402	IC₅₀	0.47 μM Compound: 2, TPT	Cytotoxicity against human Bel7402 cells after 3 days Cytotoxicity against human Bel7402 cells after 3 days	[PMID: 21333532]
Bel-7402	IC₅₀	0.1 μM Compound: 2; TPT	Antiproliferative activity against human Bel7402 cells after 96 hrs by MTT assay Antiproliferative activity against human Bel7402 cells after 96 hrs by MTT assay	[PMID: 27871039]
Bel-7402	IC₅₀	7.118 μM Compound: Topotecan	Cytotoxicity in human Bel7402 cells assessed as reduction in cell viability incubated for 48 hrs by MTT assay Cytotoxicity in human Bel7402 cells assessed as reduction in cell viability incubated for 48 hrs by MTT assay	[PMID: 30227711]
BGC-823	IC₅₀	0.0043 μM Compound: topotecan	Cytotoxicity against human BGC823 cells after 96 hrs by MTT assay Cytotoxicity against human BGC823 cells after 96 hrs by MTT assay	[PMID: 15165144]
BGC-823	IC₅₀	4.4 μM Compound: Topotecan	Cytotoxicity against human BGC823 cells after 96 hrs by MTT assay Cytotoxicity against human BGC823 cells after 96 hrs by MTT assay	[PMID: 16792409]
BGC-823	IC₅₀	3.8 μM Compound: Topotecan	Cytotoxicity against human BGC-823 cells after 96 hrs by MTT assay Cytotoxicity against human BGC-823 cells after 96 hrs by MTT assay	[PMID: 17125236]
BGC-823	IC₅₀	0.078 μM Compound: 2; TPT	Antiproliferative activity against human BGC823 cells after 96 hrs by MTT assay Antiproliferative activity against human BGC823 cells after 96 hrs by MTT assay	[PMID: 27871039]
Bone marrow cell	IC₅₀	130 nM Compound: 7	Cytotoxicity against human bone marrow cell by CFU-GM assay Cytotoxicity against human bone marrow cell by CFU-GM assay	[PMID: 21341674]
Bone marrow cell	IC₅₀	8 nM Compound: 7	Cytotoxicity against mouse bone marrow cell by CFU-GM assay Cytotoxicity against mouse bone marrow cell by CFU-GM assay	[PMID: 21341674]
BXPC-3	IC₅₀	0.62 μM Compound: 2, TPT	Cytotoxicity against human BXPC3 cells after 4 days by MTT assay Cytotoxicity against human BXPC3 cells after 4 days by MTT assay	[PMID: 18554906]
C6	IC₅₀	5.8 μM Compound: Topotecan	Antiproliferative activity against rat C6 cells assessed as inhibition of cell growth measured after 72 hrs by CCK-8 assay Antiproliferative activity against rat C6 cells assessed as inhibition of cell growth measured after 72 hrs by CCK-8 assay	[PMID: 34537445]
carcinoma cell line	IC₅₀	1.38 μM Compound: Topotecan	Cytotoxicity against human non-small-cell lung carcinoma cell line H460 (NSCLC-H460) Cytotoxicity against human non-small-cell lung carcinoma cell line H460 (NSCLC-H460)	[PMID: 11563925]
COR-L23	IC₅₀	13.2 nM Compound: Topotecan	Cytotoxicity measured using the COR-L23 parental (COR-L23/P) human non small cell lung carcinoma cell line Cytotoxicity measured using the COR-L23 parental (COR-L23/P) human non small cell lung carcinoma cell line	[PMID: 11806724]
COR-L23	IC₅₀	20 nM Compound: Topotecan	Cytotoxicity measured with the drug resistant human non small cell lung carcinoma cell line COR-L23 (COR-L23/R) which over expresses multidrug resistance associated with protein(MRP) Cytotoxicity measured with the drug resistant human non small cell lung carcinoma cell line COR-L23 (COR-L23/R) which over expresses multidrug resistance associated with protein(MRP)	[PMID: 11806724]
DU-145	GI₅₀	0.04 μM Compound: Topotecan	In vitro anti-cancer activity against DU-145 (Prostate) human tumor cell line In vitro anti-cancer activity against DU-145 (Prostate) human tumor cell line	[PMID: 10397491]
DU-145	GI₅₀	0.04 μM Compound: Topotecan	Tested in vitro for cytotoxicity against human tumor cell line DU-145 (prostate) Tested in vitro for cytotoxicity against human tumor cell line DU-145 (prostate)	[PMID: 10714502]
DU-145	IC₅₀	1.2 μM Compound: Topotecan	Antiproliferative activity against human DU145 cells by [3H]thymidine incorporation assay Antiproliferative activity against human DU145 cells by [3H]thymidine incorporation assay	[PMID: 20932758]
DU-145	IC₅₀	1 μM Compound: 7	Cytotoxicity against human DU145 cells after 72 hrs by alamar blue assay Cytotoxicity against human DU145 cells after 72 hrs by alamar blue assay	[PMID: 21341674]
DU-145	IC₅₀	40 nM Compound: 2, TPT, Hycamtin	Cytotoxicity against human DU145 cells Cytotoxicity against human DU145 cells	[PMID: 23578545]
DU-145	GI₅₀	0.01 μM Compound: 2	Growth inhibition of human DU145 cells by five-dose growth inhibition assay Growth inhibition of human DU145 cells by five-dose growth inhibition assay	[PMID: 25909279]
GES1	IC₅₀	8.55 μM Compound: TPT	Antiproliferative activity against human GES1 cells assessed as reduction in cell viability measured after 72 hrs by MTT assay Antiproliferative activity against human GES1 cells assessed as reduction in cell viability measured after 72 hrs by MTT assay	[PMID: 34774339]
GES1	IC₅₀	6.22 μM Compound: TPT	Antiproliferative activity against human GES1 cells assessed as inhibition of cell growth incubated for 72 hrs by MTT assay Antiproliferative activity against human GES1 cells assessed as inhibition of cell growth incubated for 72 hrs by MTT assay	[PMID: 34990980]
GES1	IC₅₀	1.06 μM Compound: TPT	Antiproliferative activity against human GES1 cells assessed as reduction in cell viability incubated for 72 hrs by MTT assay Antiproliferative activity against human GES1 cells assessed as reduction in cell viability incubated for 72 hrs by MTT assay	[PMID: 37099835]
H69AR	IC₅₀	>300 nM Compound: 7	Cytotoxicity against human H69AR cells overexpressing MDR1 after 72 hrs by alamar blue assay Cytotoxicity against human H69AR cells overexpressing MDR1 after 72 hrs by alamar blue assay	[PMID: 21341674]
HCT-116	IC₅₀	0.1 μM Compound: Topotecan	Inhibitory concentration against human HCT116 colon cancer cell line Inhibitory concentration against human HCT116 colon cancer cell line	[PMID: 15808456]
HCT-116	IC₅₀	1.1 μM Compound: TPT, Hycamptin	Cytotoxicity against human HCT116 cells after 3 days by MTT assay Cytotoxicity against human HCT116 cells after 3 days by MTT assay	[PMID: 21463912]
HCT-116	GI₅₀	0.4 μM Compound: TPT	Cytotoxicity against human HCT116 cells incubated for 72 hrs by MTT assay Cytotoxicity against human HCT116 cells incubated for 72 hrs by MTT assay	[PMID: 22867019]
HCT-116	IC₅₀	0.0889 μM Compound: TPT	Antiproliferative activity against human HCT116 cells after 3 days by MTT assay Antiproliferative activity against human HCT116 cells after 3 days by MTT assay	[PMID: 23084702]
HCT-116	IC₅₀	4.32 μM Compound: TPT	Antiproliferative activity against human HCT116 cells assessed as growth inhibition after 48 hrs by MTT assay Antiproliferative activity against human HCT116 cells assessed as growth inhibition after 48 hrs by MTT assay	[PMID: 24826818]
HCT-116	GI₅₀	0.03 μM Compound: 2	Growth inhibition of human HCT116 cells by five-dose growth inhibition assay Growth inhibition of human HCT116 cells by five-dose growth inhibition assay	[PMID: 25909279]
HCT-116	IC₅₀	0.7 μM Compound: TPT	Cytotoxicity against human HCT116 cells after 72 hrs by MTT assay Cytotoxicity against human HCT116 cells after 72 hrs by MTT assay	[PMID: 26226379]
HCT-116	IC₅₀	70.35 μM Compound: TPT	Antiproliferative activity against human HCT116 cells after 48 hrs by MTT assay Antiproliferative activity against human HCT116 cells after 48 hrs by MTT assay	[PMID: 26725027]
HCT-116	IC₅₀	451 nM Compound: Topotecan	Cytotoxicity against CD133 positive human HCT116 cells Cytotoxicity against CD133 positive human HCT116 cells	[PMID: 29468872]
HCT-116	IC₅₀	0.97 μM Compound: Topotecan	Antiproliferative activity against human HCT-116 cells assessed as cell growth inhibition incubated for 8 hrs by CCK8 assay Antiproliferative activity against human HCT-116 cells assessed as cell growth inhibition incubated for 8 hrs by CCK8 assay	[PMID: 35238576]
HCT-116	IC₅₀	970 nM Compound: 5; TPT	Antiproliferative activity against human HCT-116 cells assessed as reduction in cell viability measured for 48 hrs by CCK-8 assay Antiproliferative activity against human HCT-116 cells assessed as reduction in cell viability measured for 48 hrs by CCK-8 assay	[PMID: 38421819]
HCT-116	IC₅₀	5.55 μM Compound: Topotecan	Inhibition of DNA topoisomerase 1 in Homo sapiens (human) HCT116 cells Inhibition of DNA topoisomerase 1 in Homo sapiens (human) HCT116 cells	10.1007/s00044-009-9233-5
HCT-8	IC₅₀	0.074 μM Compound: Topotecan	In vitro cytotoxicity against HCT-8 (human colon cancer) In vitro cytotoxicity against HCT-8 (human colon cancer)	[PMID: 14552770]
HCT-8	IC₅₀	0.074 μM/L Compound: Topotecan	In vitro cytotoxicity against HCT-8 (human colon cancer) In vitro cytotoxicity against HCT-8 (human colon cancer)	[PMID: 14552770]
HCT-8	IC₅₀	0.0015 μM Compound: topotecan	Cytotoxicity against human HCT8 cells after 96 hrs by MTT assay Cytotoxicity against human HCT8 cells after 96 hrs by MTT assay	[PMID: 15165144]
HCT-8	IC₅₀	1.5 μM Compound: Topotecan	Cytotoxicity against human HCT8 cells after 96 hrs by MTT assay Cytotoxicity against human HCT8 cells after 96 hrs by MTT assay	[PMID: 16792409]
HCT-8	IC₅₀	1.2 μM Compound: Topotecan	Cytotoxicity against human HCT8 cells after 96 hrs by MTT assay Cytotoxicity against human HCT8 cells after 96 hrs by MTT assay	[PMID: 17125236]
HCT-8	IC₅₀	1.6 μM Compound: Topotecan	Cytotoxicity against human HCT8 cells Cytotoxicity against human HCT8 cells	[PMID: 17279797]
HCT-8	IC₅₀	3.66 μM Compound: 2, TPT	Cytotoxicity against human HCT8 cells by MTT assay Cytotoxicity against human HCT8 cells by MTT assay	[PMID: 19056266]
HCT-8	IC₅₀	0.07 μM Compound: Topotecan	Cytotoxicity against human HCT8 cells after 3 days by MTT assay Cytotoxicity against human HCT8 cells after 3 days by MTT assay	[PMID: 20392545]
HCT-8	IC₅₀	0.07 nM/mL Compound: Topotecan	Cytotoxicity against human HCT8 cells after 3 days by MTT assay Cytotoxicity against human HCT8 cells after 3 days by MTT assay	[PMID: 20392545]
HCT-8	IC₅₀	0.022 μM Compound: 2; TPT	Antiproliferative activity against human HCT8 cells after 96 hrs by MTT assay Antiproliferative activity against human HCT8 cells after 96 hrs by MTT assay	[PMID: 27871039]
HEK293	IC₅₀	1.3 μM Compound: topotecan	Inhibition of human MATE1-mediated ASP+ uptake expressed in HEK293 cells after 1.5 mins by fluorescence assay Inhibition of human MATE1-mediated ASP+ uptake expressed in HEK293 cells after 1.5 mins by fluorescence assay	[PMID: 23241029]
HEK293	IC₅₀	61 μM Compound: topotecan	Inhibition of human OCT2-mediated ASP+ uptake expressed in HEK293 cells after 3 mins by fluorescence assay Inhibition of human OCT2-mediated ASP+ uptake expressed in HEK293 cells after 3 mins by fluorescence assay	[PMID: 23241029]
HEK293	IC₅₀	8.6 μM Compound: topotecan	Inhibition of human MATE2K-mediated ASP+ uptake expressed in HEK293 cells after 1.5 mins by fluorescence assay Inhibition of human MATE2K-mediated ASP+ uptake expressed in HEK293 cells after 1.5 mins by fluorescence assay	[PMID: 23241029]
HEL	IC₅₀	26 μM Compound: Topotecan	Antiproliferative activity against HEL cells assessed as cell growth inhibition incubated for 8 hrs by CCK8 assay Antiproliferative activity against HEL cells assessed as cell growth inhibition incubated for 8 hrs by CCK8 assay	[PMID: 35238576]
HeLa	GI₅₀	0.03 μM Compound: topotecan	Growth inhibition of HeLa cells after 4 days Growth inhibition of HeLa cells after 4 days	[PMID: 17418582]
HeLa	GI₅₀	0.08 μM Compound: 3, TPT	Cytotoxicity against p53-deficient human HeLa cells after 48 hrs by SRB assay Cytotoxicity against p53-deficient human HeLa cells after 48 hrs by SRB assay	[PMID: 19715319]
HeLa	IC₅₀	1.6 μM Compound: 3, TPT	Cytotoxicity against p53-deficient human HeLa cells after 48 hrs by SRB assay Cytotoxicity against p53-deficient human HeLa cells after 48 hrs by SRB assay	[PMID: 19715319]
HeLa	IC₅₀	376 nM Compound: Topotecan	Cytotoxicity against human HeLa cells after 72 hrs by MTT assay Cytotoxicity against human HeLa cells after 72 hrs by MTT assay	[PMID: 24900725]
HeLa	IC₅₀	0.73 μM Compound: Topotecan	Inhibition of DNA topoisomerase 2 in human HeLa cells incubated for 18 to 24 hrs by kinase assay Inhibition of DNA topoisomerase 2 in human HeLa cells incubated for 18 to 24 hrs by kinase assay	[PMID: 31416740]
HeLa	CC₅₀	4.5 μM Compound: Tpc	Cytotoxicity against human HeLa cells assessed as reduction in cell viability after 3 days by fluorometric assay Cytotoxicity against human HeLa cells assessed as reduction in cell viability after 3 days by fluorometric assay	[PMID: 32786885]
HeLa	IC₅₀	376 nM Compound: 5; TPT	Antiproliferative activity against human HeLa cells assessed as reduction in cell viability measured for 48 hrs by CCK-8 assay Antiproliferative activity against human HeLa cells assessed as reduction in cell viability measured for 48 hrs by CCK-8 assay	[PMID: 38421819]
Hep 3B2	GI₅₀	0.4 μM Compound: 3, TPT	Cytotoxicity against p53-deficient human Hep3B cells after 48 hrs by SRB assay Cytotoxicity against p53-deficient human Hep3B cells after 48 hrs by SRB assay	[PMID: 19715319]
Hep 3B2	IC₅₀	1.4 μM Compound: 3, TPT	Cytotoxicity against p53-deficient human Hep3B cells after 48 hrs by SRB assay Cytotoxicity against p53-deficient human Hep3B cells after 48 hrs by SRB assay	[PMID: 19715319]
Hep 3B2	GI₅₀	0.22 μM Compound: Topotecan	Antiproliferative activity against human Hep3B cells after 72 hrs by XTT assay Antiproliferative activity against human Hep3B cells after 72 hrs by XTT assay	[PMID: 19796956]
Hep 3B2	GI₅₀	0.22 μM Compound: Topotecan	Growth inhibition of human Hep3B cells after 72 hrs by XTT assay Growth inhibition of human Hep3B cells after 72 hrs by XTT assay	[PMID: 22079254]
Hep 3B2	IC₅₀	7.9 nM Compound: Topotecan	Cytotoxicity against human Hep3B cells assessed as growth inhibition measured after 72 hrs by MTT assay Cytotoxicity against human Hep3B cells assessed as growth inhibition measured after 72 hrs by MTT assay	[PMID: 31881457]
HepG2	IC₅₀	0.06 μM Compound: 2, TPT	Cytotoxicity against human HepG2 cells after 4 days by MTT assay Cytotoxicity against human HepG2 cells after 4 days by MTT assay	[PMID: 18554906]
HepG2	GI₅₀	1.2 μM Compound: 3, TPT	Cytotoxicity against human HepG2 cells expressing wild type p53 after 48 hrs by SRB assay Cytotoxicity against human HepG2 cells expressing wild type p53 after 48 hrs by SRB assay	[PMID: 19715319]
HepG2	IC₅₀	1.6 μM Compound: 3, TPT	Cytotoxicity against human HepG2 cells expressing wild type p53 after 48 hrs by SRB assay Cytotoxicity against human HepG2 cells expressing wild type p53 after 48 hrs by SRB assay	[PMID: 19715319]
HepG2	GI₅₀	3.83 μM Compound: Topotecan	Antiproliferative activity against human HepG2 cells after 72 hrs by XTT assay Antiproliferative activity against human HepG2 cells after 72 hrs by XTT assay	[PMID: 19796956]
HepG2	GI₅₀	3.83 μM Compound: Topotecan	Growth inhibition of human HepG2 cells after 72 hrs by XTT assay Growth inhibition of human HepG2 cells after 72 hrs by XTT assay	[PMID: 22079254]
HepG2	IC₅₀	1.66 μM Compound: TPT	Antiproliferative activity against human HepG2 cells assessed as growth inhibition after 48 hrs by MTT assay Antiproliferative activity against human HepG2 cells assessed as growth inhibition after 48 hrs by MTT assay	[PMID: 24826818]
HepG2	IC₅₀	2.55 μM Compound: TPT	Antiproliferative activity against human HepG2 cells after 48 hrs by MTT assay Antiproliferative activity against human HepG2 cells after 48 hrs by MTT assay	[PMID: 26725027]
HepG2	IC₅₀	0.237 μM Compound: Topotecan	Cytotoxicity in human HepG2 cells assessed as reduction in cell viability incubated for 48 hrs by MTT assay Cytotoxicity in human HepG2 cells assessed as reduction in cell viability incubated for 48 hrs by MTT assay	[PMID: 30227711]
HepG2	IC₅₀	3.28 μM Compound: TPT	Antiproliferative activity against human HepG2 cells assessed as inhibition of cell growth incubated for 72 hrs by MTT assay Antiproliferative activity against human HepG2 cells assessed as inhibition of cell growth incubated for 72 hrs by MTT assay	[PMID: 34990980]
HepG2	IC₅₀	3.3 μM Compound: Topotecan	Antiproliferative activity against human HepG2 cells assessed as cell growth inhibition incubated for 8 hrs by CCK8 assay Antiproliferative activity against human HepG2 cells assessed as cell growth inhibition incubated for 8 hrs by CCK8 assay	[PMID: 35238576]
HepG2	IC₅₀	60 nM Compound: 5; TPT	Antiproliferative activity against human HepG2 cells assessed as reduction in cell viability measured for 48 hrs by CCK-8 assay Antiproliferative activity against human HepG2 cells assessed as reduction in cell viability measured for 48 hrs by CCK-8 assay	[PMID: 38421819]
HGC-27	IC₅₀	10.82 μM Compound: TPT	Antiproliferative activity against human HGC-27 cells assessed as reduction in cell viability measured after 72 hrs by MTT assay Antiproliferative activity against human HGC-27 cells assessed as reduction in cell viability measured after 72 hrs by MTT assay	[PMID: 34774339]
HGC-27	IC₅₀	0.22 μM Compound: TPT	Antiproliferative activity against human HGC-27 cells assessed as inhibition of cell growth incubated for 72 hrs by MTT assay Antiproliferative activity against human HGC-27 cells assessed as inhibition of cell growth incubated for 72 hrs by MTT assay	[PMID: 34990980]
HGC-27	IC₅₀	10.82 μM Compound: TPT	Antiproliferative activity against human HGC-27 cells assessed as inhibition of cell proliferation incubated for 72 hrs by MTT assay Antiproliferative activity against human HGC-27 cells assessed as inhibition of cell proliferation incubated for 72 hrs by MTT assay	[PMID: 35728506]
HGC-27	IC₅₀	0.49 μM Compound: TPT	Antiproliferative activity against human HGC-27 cells assessed as reduction in cell viability incubated for 72 hrs by MTT assay Antiproliferative activity against human HGC-27 cells assessed as reduction in cell viability incubated for 72 hrs by MTT assay	[PMID: 37099835]
HL-60	IC₅₀	0.012 μM Compound: 3	Antitumor activity against human HL60 cells by SRB method Antitumor activity against human HL60 cells by SRB method	[PMID: 19541483]
HL-60	IC₅₀	0.052 μM Compound: 2, TPT	Cytotoxicity against human HL60 cells after 3 days Cytotoxicity against human HL60 cells after 3 days	[PMID: 21333532]
HL-60	IC₅₀	1 μM Compound: 5al	Inhibition of Topoisomerase I by cleavage complex formation in human HL-60 cells Inhibition of Topoisomerase I by cleavage complex formation in human HL-60 cells	[PMID: 8410981]
HMLE	IC₅₀	0.75 μM Compound: TPT	Antiproliferative activity against human HMLE cells assessed as reduction in cell viability by MTT assay Antiproliferative activity against human HMLE cells assessed as reduction in cell viability by MTT assay	[PMID: 28197320]
HOP-62	GI₅₀	0.05 μM Compound: Topotecan	In vitro anti-cancer activity against HOP 62(Lung) human tumor cell line In vitro anti-cancer activity against HOP 62(Lung) human tumor cell line	[PMID: 10397491]
HOP-62	GI₅₀	0.05 μM Compound: Topotecan	Tested in vitro for cytotoxicity against human tumor cell line HOP62 (lung) Tested in vitro for cytotoxicity against human tumor cell line HOP62 (lung)	[PMID: 10714502]
HOP-62	GI₅₀	0.01 μM Compound: 2	Growth inhibition of human HOP62 cells by five-dose growth inhibition assay Growth inhibition of human HOP62 cells by five-dose growth inhibition assay	[PMID: 25909279]
HT-1080	IC₅₀	0.18 μM Compound: Topotecan	Antiproliferative activity against human HT1080 cells assessed as growth inhibition incubated for 48 hrs by sulforhodamine B assay Antiproliferative activity against human HT1080 cells assessed as growth inhibition incubated for 48 hrs by sulforhodamine B assay	[PMID: 26408815]
HT-1080	IC₅₀	0.5 μM Compound: Tpt	Antiproliferative activity against human HT1080 cells after 48 hrs by SRB assay Antiproliferative activity against human HT1080 cells after 48 hrs by SRB assay	[PMID: 29936355]
HT-29	IC₅₀	1.35 μM Compound: topotecan	Antiproliferative activity against human HT29 cells after 1 hr of drug exposure measured after 72 hrs Antiproliferative activity against human HT29 cells after 1 hr of drug exposure measured after 72 hrs	[PMID: 18424133]
HT-29	IC₅₀	46.29 μM Compound: topotecan	Antiproliferative activity against BCRP overexpressing mitoxantrone-resistant human HT29 cells after 1 hr of drug exposure measured after 72 hrs Antiproliferative activity against BCRP overexpressing mitoxantrone-resistant human HT29 cells after 1 hr of drug exposure measured after 72 hrs	[PMID: 18424133]
HT-29	IC₅₀	0.88 μM Compound: 2, TPT	Cytotoxicity against human HT29 cells after 4 days by MTT assay Cytotoxicity against human HT29 cells after 4 days by MTT assay	[PMID: 18554906]
HT-29	IC₅₀	0.375 μM Compound: Topotecan	Cytotoxicity against human HT-29 cells by SRB method Cytotoxicity against human HT-29 cells by SRB method	[PMID: 18986807]
HT-29	IC₅₀	0.41 μM Compound: 3	Antitumor activity against human HT-29 cells by SRB method Antitumor activity against human HT-29 cells by SRB method	[PMID: 19541483]
HT-29	GI₅₀	0.08 μM Compound: 3, TPT	Cytotoxicity against human HT-29 cells expressing p53 mutant after 48 hrs by SRB assay Cytotoxicity against human HT-29 cells expressing p53 mutant after 48 hrs by SRB assay	[PMID: 19715319]
HT-29	IC₅₀	0.4 μM Compound: 3, TPT	Cytotoxicity against human HT-29 cells expressing p53 mutant after 48 hrs by SRB assay Cytotoxicity against human HT-29 cells expressing p53 mutant after 48 hrs by SRB assay	[PMID: 19715319]
HT-29	IC₅₀	>1000 nM Compound: 7	Cytotoxicity against human HT-29 cells after 72 hrs by alamar blue assay Cytotoxicity against human HT-29 cells after 72 hrs by alamar blue assay	[PMID: 21341674]
HT-29	IC₅₀	40 nM Compound: 2, TPT, Hycamtin	Cytotoxicity against human HT-29 cells Cytotoxicity against human HT-29 cells	[PMID: 23578545]
HT-29	IC₅₀	0.23 μM Compound: Topotecan	Antiproliferative activity against human HT-29 cells assessed as growth inhibition incubated for 48 hrs by sulforhodamine B assay Antiproliferative activity against human HT-29 cells assessed as growth inhibition incubated for 48 hrs by sulforhodamine B assay	[PMID: 26408815]
HT-29	IC₅₀	0.41 μM Compound: Tpt	Antiproliferative activity against human HT-29 cells after 48 hrs by SRB assay Antiproliferative activity against human HT-29 cells after 48 hrs by SRB assay	[PMID: 29936355]
HT-29	IC₅₀	3.28 μM Compound: TPT	Antiproliferative activity against human HT-29 cells assessed as inhibition of cell growth incubated for 72 hrs by MTT assay Antiproliferative activity against human HT-29 cells assessed as inhibition of cell growth incubated for 72 hrs by MTT assay	[PMID: 34990980]
HT-29	IC₅₀	25 nM Compound: Topotecan	Cytotoxicity was determined in vitro in HT-29 cells(colon) of human tumor cell lines by using MTT assay Cytotoxicity was determined in vitro in HT-29 cells(colon) of human tumor cell lines by using MTT assay	[PMID: 7853331]
HT-29	IC₅₀	25 nM Compound: 3	Human tumor cell cytotoxicity assay was performed using MTT (HT-29 cell line ) Human tumor cell cytotoxicity assay was performed using MTT (HT-29 cell line )	[PMID: 8576914]
Huh-7	IC₅₀	8.61 μM Compound: Topotecan	Antiproliferative activity against human HuH7 cells after 3 days by XTT assay Antiproliferative activity against human HuH7 cells after 3 days by XTT assay	[PMID: 24727241]
Huh-7	IC₅₀	8.61 μM Compound: Topotecan	Antiproliferative activity against human HuH7 cells after 72 hrs by XTT assay Antiproliferative activity against human HuH7 cells after 72 hrs by XTT assay	[PMID: 26686931]
IGROV-1	IC₅₀	160 nM Compound: 7	Cytotoxicity against human IGROV1 cells after 72 hrs by alamar blue assay Cytotoxicity against human IGROV1 cells after 72 hrs by alamar blue assay	[PMID: 21341674]
K562	IC₅₀	1.7 μM Compound: 3, TPT	Cytotoxicity against p53-deficient human K562 cells after 48 hrs by SRB assay Cytotoxicity against p53-deficient human K562 cells after 48 hrs by SRB assay	[PMID: 19715319]
K562	IC₅₀	500 nM Compound: Topotecan	Cytotoxicity against human K562 cells after 72 hrs by MTT assay Cytotoxicity against human K562 cells after 72 hrs by MTT assay	[PMID: 24900725]
K562	IC₅₀	1.15 μM Compound: TPT	Antiproliferative activity against human K562 cells assessed as reduction in cell viability by MTT assay Antiproliferative activity against human K562 cells assessed as reduction in cell viability by MTT assay	[PMID: 28197320]
K562	IC₅₀	0.91 μM Compound: Topotecan	Antiproliferative activity against human K562 cells assessed as cell growth inhibition incubated for 8 hrs by CCK8 assay Antiproliferative activity against human K562 cells assessed as cell growth inhibition incubated for 8 hrs by CCK8 assay	[PMID: 35238576]
K562	IC₅₀	500 nM Compound: 5; TPT	Antiproliferative activity against human K562 cells assessed as reduction in cell viability measured for 48 hrs by CCK-8 assay Antiproliferative activity against human K562 cells assessed as reduction in cell viability measured for 48 hrs by CCK-8 assay	[PMID: 38421819]
K562	IC₅₀	1100 nM Compound: TPT	Antiproliferative activity measured against K562adr leukemia cells. Antiproliferative activity measured against K562adr leukemia cells.	[PMID: 9876111]
KB	IC₅₀	0.062 μM Compound: Topotecan	In vitro cytotoxicity against KB (human epidermoid carcinoma of the nasopharynx) In vitro cytotoxicity against KB (human epidermoid carcinoma of the nasopharynx)	[PMID: 14552770]
KB	IC₅₀	0.062 μM/L Compound: Topotecan	In vitro cytotoxicity against KB (human epidermoid carcinoma of the nasopharynx) In vitro cytotoxicity against KB (human epidermoid carcinoma of the nasopharynx)	[PMID: 14552770]
KB	IC₅₀	0.44 μM Compound: Topotecan	Concentration required to inhibit cell proliferation in KBV-1 tumor cell line; overexpress MDR1 Concentration required to inhibit cell proliferation in KBV-1 tumor cell line; overexpress MDR1	[PMID: 15482929]
KB	IC₅₀	0.22 μM Compound: 2, TPT	Cytotoxicity against human KB cells after 4 days by MTT assay Cytotoxicity against human KB cells after 4 days by MTT assay	[PMID: 18554906]
KB	IC₅₀	0.07 μM Compound: Topotecan	Cytotoxicity against human KB cells after 3 days by MTT assay Cytotoxicity against human KB cells after 3 days by MTT assay	[PMID: 20392545]
KB	IC₅₀	0.07 nM/mL Compound: Topotecan	Cytotoxicity against human KB cells after 3 days by MTT assay Cytotoxicity against human KB cells after 3 days by MTT assay	[PMID: 20392545]
KB	IC₅₀	>200 μM Compound: TPT	Antiproliferative activity against human KB cells assessed as growth inhibition after 48 hrs by MTT assay Antiproliferative activity against human KB cells assessed as growth inhibition after 48 hrs by MTT assay	[PMID: 24826818]
KB	IC₅₀	0.0625 μM Compound: 2	Cytotoxicity against human KB cells after 72 hrs sulforhodamine B colorimetric assay Cytotoxicity against human KB cells after 72 hrs sulforhodamine B colorimetric assay	[PMID: 25008456]
KB	IC₅₀	0.063 μM Compound: 2	Cytotoxicity against human KB cells after 72 hrs by SRB assay Cytotoxicity against human KB cells after 72 hrs by SRB assay	[PMID: 25438769]
KB	IC₅₀	102 nM Compound: 3	Cytotoxicity against human KB cells after 72 hrs by sulforhodamine B assay Cytotoxicity against human KB cells after 72 hrs by sulforhodamine B assay	[PMID: 28285912]
KB	IC₅₀	0.101 μM Compound: 3; TPT	Cytotoxicity against human KB cells after 72 hrs by SRB assay Cytotoxicity against human KB cells after 72 hrs by SRB assay	[PMID: 28789891]
KB	IC₅₀	102 nM Compound: 3	Cytotoxicity against human KB cells after 72 hrs by SRB assay Cytotoxicity against human KB cells after 72 hrs by SRB assay	[PMID: 28927790]
KB	IC₅₀	2.61 μM Compound: Topotecan	Cytotoxicity in human KB cells assessed as reduction in cell viability incubated for 48 hrs by MTT assay Cytotoxicity in human KB cells assessed as reduction in cell viability incubated for 48 hrs by MTT assay	[PMID: 30227711]
KB	IC₅₀	71.8 nM Compound: Topotecan	Cytotoxicity against human KB cells assessed as growth inhibition measured after 72 hrs by MTT assay Cytotoxicity against human KB cells assessed as growth inhibition measured after 72 hrs by MTT assay	[PMID: 31881457]
KB 3-1	IC₅₀	0.04 μM Compound: Topotecan	Concentration required to inhibit cell proliferation in KB3-1 tumor cell line Concentration required to inhibit cell proliferation in KB3-1 tumor cell line	[PMID: 15482929]
KB 3-1	IC₅₀	0.44 μM Compound: Topotecan	Concentration required to inhibit cell proliferation in KBH5.0 tumor cell line; overexpress BCRP Concentration required to inhibit cell proliferation in KBH5.0 tumor cell line; overexpress BCRP	[PMID: 15482929]
KB 3-1	IC₅₀	0.04 μM Compound: Topotecan	Inhibitory concentration against KB3-1 cell line was determined Inhibitory concentration against KB3-1 cell line was determined	[PMID: 15689163]
KB 3-1	IC₅₀	0.44 μM Compound: Topotecan	Inhibitory concentration against KB/V-1 cells overexpress MDR1 Inhibitory concentration against KB/V-1 cells overexpress MDR1	[PMID: 15689163]
KB 3-1	IC₅₀	0.04 μM Compound: topotecan	Cytotoxicity against human KB3-1 cells by MTT method Cytotoxicity against human KB3-1 cells by MTT method	[PMID: 18771930]
KB 3-1	IC₅₀	0.04 μM Compound: Topotecan	Cytotoxicity against human KB3-1 cells after MTT assay Cytotoxicity against human KB3-1 cells after MTT assay	[PMID: 18829334]
KB 3-1	IC₅₀	0.04 μM Compound: Topotecan	Cytotoxicity against human KB3-1 cells by MTT method Cytotoxicity against human KB3-1 cells by MTT method	[PMID: 19012996]
KB 3-1	IC₅₀	0.04 μM Compound: TPT	Cytotoxicity against human KB3-1 cells after 4 days by MTT method Cytotoxicity against human KB3-1 cells after 4 days by MTT method	[PMID: 19303306]
KB VCR R	IC₅₀	0.339 μM Compound: Topotecan	In vitro cytotoxicity against KB/VCR (Vincristine-resistant cancer cell line) In vitro cytotoxicity against KB/VCR (Vincristine-resistant cancer cell line)	[PMID: 14552770]
KB-V1	IC₅₀	0.44 μM Compound: topotecan	Cytotoxicity against human KBV1 cells by MTT method Cytotoxicity against human KBV1 cells by MTT method	[PMID: 18771930]
KB-V1	IC₅₀	0.44 μM Compound: Topotecan	Cytotoxicity against multidrug resistant human KBV-1 cells overexpressing MDR1 after MTT assay Cytotoxicity against multidrug resistant human KBV-1 cells overexpressing MDR1 after MTT assay	[PMID: 18829334]
KB-V1	IC₅₀	0.44 μM Compound: Topotecan	Cytotoxicity against multidrug resistant human KBV1 cells overexpressing MDR1 by MTT method Cytotoxicity against multidrug resistant human KBV1 cells overexpressing MDR1 by MTT method	[PMID: 19012996]
KB-V1	IC₅₀	0.44 μM Compound: TPT	Cytotoxicity against MDR1 overexpressing human KBV1 cells after 4 days by MTT method Cytotoxicity against MDR1 overexpressing human KBV1 cells after 4 days by MTT method	[PMID: 19303306]
KETR3	IC₅₀	0.0049 μM Compound: topotecan	Cytotoxicity against human Ketr3 cells after 96 hrs by MTT assay Cytotoxicity against human Ketr3 cells after 96 hrs by MTT assay	[PMID: 15165144]
L1210	IC₅₀	0.1 μM Compound: Topotecan	Inhibitory concentration against L1210 leukemia cell proliferation Inhibitory concentration against L1210 leukemia cell proliferation	[PMID: 12873503]
L1210	IC₅₀	56 nM Compound: 4	Inhibitory activity in mice bearing L1210 leukemia Inhibitory activity in mice bearing L1210 leukemia	[PMID: 1846923]
L1210	IC₅₀	0.1 μM Compound: 2, TPT, Hycamtin	Cytotoxicity against mouse L1210 cells Cytotoxicity against mouse L1210 cells	[PMID: 23578545]
L1210	IC₅₀	56 nM Compound: 5; TPT	Antiproliferative activity against mouse L1210 cells assessed as inhibition of cell growth incubated for 24 hrs by MTT assay Antiproliferative activity against mouse L1210 cells assessed as inhibition of cell growth incubated for 24 hrs by MTT assay	[PMID: 38421819]
L1210	IC₅₀	601 nM Compound: TPT	Compound was evaluated for cytotoxic activity on L1210 murine leukemia cells Compound was evaluated for cytotoxic activity on L1210 murine leukemia cells	10.1016/S0960-894X(97)00398-3
LNCaP	IC₅₀	9 nM Compound: 7	Cytotoxicity against human LNCAP cells after 72 hrs by alamar blue assay Cytotoxicity against human LNCAP cells after 72 hrs by alamar blue assay	[PMID: 21341674]
LoVo	IC₅₀	11.6 nM Compound: Topotecan	Cytotoxic potentiation of Topotecan (TP) by the compound in (human colorectal cancer LoVo cell line Cytotoxic potentiation of Topotecan (TP) by the compound in (human colorectal cancer LoVo cell line	[PMID: 12408707]
LoVo	IC₅₀	0.036 μM Compound: topotecan, TPT	Antitumor activity against human LOVO cells after 4 hrs by MTT assay Antitumor activity against human LOVO cells after 4 hrs by MTT assay	[PMID: 18207748]
LoVo	IC₅₀	1.21 μM Compound: Topotecan	Cytotoxicity against human LoVo cells after 3 days by MTT assay Cytotoxicity against human LoVo cells after 3 days by MTT assay	[PMID: 20202723]
LoVo	IC₅₀	0.02 μM Compound: 2, Hycamtin	Cytotoxicity against human LoVo cells after 72 hrs by MTT assay Cytotoxicity against human LoVo cells after 72 hrs by MTT assay	[PMID: 20371183]
LoVo	IC₅₀	0.12 μM Compound: TPT	Antiproliferative activity against human LoVo cells assessed as reduction in cell viability incubated for 72 hrs by MTT assay Antiproliferative activity against human LoVo cells assessed as reduction in cell viability incubated for 72 hrs by MTT assay	[PMID: 37099835]
LOX IMVI	IC₅₀	5 nM Compound: Topotecan	Cytotoxicity was determined in vitro in LOX cells (melanoma) of human tumor cell lines by using MTT assay Cytotoxicity was determined in vitro in LOX cells (melanoma) of human tumor cell lines by using MTT assay	[PMID: 7853331]
M21	IC₅₀	1.4 μM Compound: Topotecan	Antiproliferative activity against human M21 cells assessed as growth inhibition incubated for 48 hrs by sulforhodamine B assay Antiproliferative activity against human M21 cells assessed as growth inhibition incubated for 48 hrs by sulforhodamine B assay	[PMID: 26408815]
M21	IC₅₀	1.4 μM Compound: Tpt	Antiproliferative activity against human M21 cells after 48 hrs by SRB assay Antiproliferative activity against human M21 cells after 48 hrs by SRB assay	[PMID: 29936355]
Malme-3M	IC₅₀	1 μM Compound: 7	Cytotoxicity against human MALME-3M cells after 72 hrs by alamar blue assay Cytotoxicity against human MALME-3M cells after 72 hrs by alamar blue assay	[PMID: 21341674]
MCF7	IC₅₀	0.0018 μM Compound: topotecan	Cytotoxicity against human MCF7 cells after 96 hrs by MTT assay Cytotoxicity against human MCF7 cells after 96 hrs by MTT assay	[PMID: 15165144]
MCF7	IC₅₀	1.9 μM Compound: Topotecan	Cytotoxicity against human MCF7 cells after 96 hrs by MTT assay Cytotoxicity against human MCF7 cells after 96 hrs by MTT assay	[PMID: 16792409]
MCF7	GI₅₀	0.04 μM Compound: topotecan	Growth inhibition of adriamycin-resistant MCF7 cells after 4 days Growth inhibition of adriamycin-resistant MCF7 cells after 4 days	[PMID: 17418582]
MCF7	GI₅₀	0.05 μM Compound: topotecan	Growth inhibition of MCF7 cells after 4 days Growth inhibition of MCF7 cells after 4 days	[PMID: 17418582]
MCF7	IC₅₀	0.488 μM Compound: topotecan, TPT	Antitumor activity against human MCF7 cells after 4 hrs by MTT assay Antitumor activity against human MCF7 cells after 4 hrs by MTT assay	[PMID: 18207748]
MCF7	IC₅₀	1.2 μM Compound: 2, TPT	Cytotoxicity against human MCF7 cells after 4 days by MTT assay Cytotoxicity against human MCF7 cells after 4 days by MTT assay	[PMID: 18554906]
MCF7	IC₅₀	5.55 μM Compound: 2, TPT	Cytotoxicity against human MCF7 cells by MTT assay Cytotoxicity against human MCF7 cells by MTT assay	[PMID: 19056266]
MCF7	GI₅₀	0.8 μM Compound: 3, TPT	Cytotoxicity against estrogen receptor-positive human MCF7 cells expressing wild type p53 after 48 hrs by SRB assay Cytotoxicity against estrogen receptor-positive human MCF7 cells expressing wild type p53 after 48 hrs by SRB assay	[PMID: 19715319]
MCF7	IC₅₀	2 μM Compound: 3, TPT	Cytotoxicity against estrogen receptor-positive human MCF7 cells expressing wild type p53 after 48 hrs by SRB assay Cytotoxicity against estrogen receptor-positive human MCF7 cells expressing wild type p53 after 48 hrs by SRB assay	[PMID: 19715319]
MCF7	IC₅₀	0.15 μM Compound: Topotecan	Cytotoxicity against human MCF7 cells after 3 days by MTT assay Cytotoxicity against human MCF7 cells after 3 days by MTT assay	[PMID: 20392545]
MCF7	IC₅₀	0.15 nM/mL Compound: Topotecan	Cytotoxicity against human MCF7 cells after 3 days by MTT assay Cytotoxicity against human MCF7 cells after 3 days by MTT assay	[PMID: 20392545]
MCF7	GI₅₀	>10 μM Compound: Topotecan	Growth inhibition of human MCF7 cells after 72 hrs by XTT assay Growth inhibition of human MCF7 cells after 72 hrs by XTT assay	[PMID: 22079254]
MCF7	IC₅₀	5.97 μM Compound: Top	Antiproliferative activity against human MCF7 cells after 72 hrs by XTT assay Antiproliferative activity against human MCF7 cells after 72 hrs by XTT assay	[PMID: 23237975]
MCF7	IC₅₀	5.97 μM Compound: Topotecan	Antiproliferative activity against human MCF7 cells after 3 days by XTT assay Antiproliferative activity against human MCF7 cells after 3 days by XTT assay	[PMID: 24727241]
MCF7	IC₅₀	14.3 μM Compound: TPT	Antiproliferative activity against human MCF7 cells assessed as growth inhibition after 48 hrs by MTT assay Antiproliferative activity against human MCF7 cells assessed as growth inhibition after 48 hrs by MTT assay	[PMID: 24826818]
MCF7	IC₅₀	63 nM Compound: Topotecan	Cytotoxicity against human MCF7 cells after 72 hrs by MTT assay Cytotoxicity against human MCF7 cells after 72 hrs by MTT assay	[PMID: 24900725]
MCF7	IC₅₀	3.46 μM Compound: Topotecan	Antiproliferative activity against human MCF7 cells after 24 hrs by MTT assay Antiproliferative activity against human MCF7 cells after 24 hrs by MTT assay	[PMID: 25147141]
MCF7	GI₅₀	0.01 μM Compound: 2	Growth inhibition of human MCF7 cells by five-dose growth inhibition assay Growth inhibition of human MCF7 cells by five-dose growth inhibition assay	[PMID: 25909279]
MCF7	IC₅₀	0.024 μM Compound: Topotecan	Antiproliferative activity against human MCF7 cells assessed as growth inhibition incubated for 48 hrs by sulforhodamine B assay Antiproliferative activity against human MCF7 cells assessed as growth inhibition incubated for 48 hrs by sulforhodamine B assay	[PMID: 26408815]
MCF7	IC₅₀	666 nM Compound: 3	Cytotoxicity against human MCF7 cells after 72 hrs by sulforhodamine B assay Cytotoxicity against human MCF7 cells after 72 hrs by sulforhodamine B assay	[PMID: 28285912]
MCF7	IC₅₀	0.28 μM Compound: 3; TPT	Cytotoxicity against human MCF7 cells after 72 hrs by SRB assay Cytotoxicity against human MCF7 cells after 72 hrs by SRB assay	[PMID: 28789891]
MCF7	IC₅₀	666 nM Compound: 3	Cytotoxicity against human MCF7 cells after 72 hrs by SRB assay Cytotoxicity against human MCF7 cells after 72 hrs by SRB assay	[PMID: 28927790]
MCF7	IC₅₀	0.2 μM Compound: Tpt	Antiproliferative activity against human MCF7 cells after 48 hrs by SRB assay Antiproliferative activity against human MCF7 cells after 48 hrs by SRB assay	[PMID: 29936355]
MCF7	IC₅₀	2.135 μM Compound: Topotecan	Cytotoxicity in human MCF7 cells assessed as reduction in cell viability incubated for 48 hrs by MTT assay Cytotoxicity in human MCF7 cells assessed as reduction in cell viability incubated for 48 hrs by MTT assay	[PMID: 30227711]
MCF7	IC₅₀	1.8 μM Compound: Topotecan	Poison activity at TOP1 in human MCF7 cells assessed as decrease in relaxed supercoiled pBS(SK+) DNA mobility measured after 30 mins by ethidium bromide staining based agarose gel electrophoresis Poison activity at TOP1 in human MCF7 cells assessed as decrease in relaxed supercoiled pBS(SK+) DNA mobility measured after 30 mins by ethidium bromide staining based agarose gel electrophoresis	[PMID: 30897325]
MCF7	IC₅₀	0.48 μM Compound: Topotecan	Inhibition of DNA topoisomerase 2 in human MCF7 cells incubated for 18 to 24 hrs by kinase assay Inhibition of DNA topoisomerase 2 in human MCF7 cells incubated for 18 to 24 hrs by kinase assay	[PMID: 31416740]
MCF7	IC₅₀	34.5 nM Compound: Topotecan	Cytotoxicity against human MCF7 cells assessed as growth inhibition measured after 72 hrs by MTT assay Cytotoxicity against human MCF7 cells assessed as growth inhibition measured after 72 hrs by MTT assay	[PMID: 31881457]
MCF7	GI₅₀	0.35 μM Compound: TPT	Cytotoxicity against human MCF-7 cells assessed as cell growth inhibition after 72 hrs by MTT assay Cytotoxicity against human MCF-7 cells assessed as cell growth inhibition after 72 hrs by MTT assay	[PMID: 34008967]
MCF7	GI₅₀	2.59 μM Compound: TPT	Cytotoxicity against human MCF-7/TDP1 cells assessed as cell growth inhibition after 72 hrs by MTT assay Cytotoxicity against human MCF-7/TDP1 cells assessed as cell growth inhibition after 72 hrs by MTT assay	[PMID: 34008967]
MCF7	IC₅₀	0.26 μM Compound: TPT	Antiproliferative activity against human MCF7 cells assessed as inhibition of cell growth incubated for 72 hrs by MTT assay Antiproliferative activity against human MCF7 cells assessed as inhibition of cell growth incubated for 72 hrs by MTT assay	[PMID: 34990980]
MCF7	IC₅₀	0.14 μM Compound: Topotecan	Antiproliferative activity against human MCF7 cells assessed as cell growth inhibition incubated for 8 hrs by CCK8 assay Antiproliferative activity against human MCF7 cells assessed as cell growth inhibition incubated for 8 hrs by CCK8 assay	[PMID: 35238576]
MCF7	IC₅₀	420 nM Compound: 5; TPT	Antiproliferative activity against human MCF7 cells assessed as reduction in cell viability measured for 48 hrs by CCK-8 assay Antiproliferative activity against human MCF7 cells assessed as reduction in cell viability measured for 48 hrs by CCK-8 assay	[PMID: 38421819]
MCF7	IC₅₀	420 nM Compound: TPT	Antiproliferative activity measured against MCF-7-mdr cells. Antiproliferative activity measured against MCF-7-mdr cells.	[PMID: 9876111]
MDA-MB-231	GI₅₀	2.25 μM Compound: Topotecan	Growth inhibition of human MDA-MB-231 cells expressing p53 mutant assessed as reduction in cell growth incubated for 48 hrs Growth inhibition of human MDA-MB-231 cells expressing p53 mutant assessed as reduction in cell growth incubated for 48 hrs	[PMID: 18790776]
MDA-MB-231	GI₅₀	0.078 μM Compound: Topotecan	Growth inhibition of human MDA-MB-231 cells after 72 hrs by XTT assay Growth inhibition of human MDA-MB-231 cells after 72 hrs by XTT assay	[PMID: 22079254]
MDA-MB-231	IC₅₀	<0.1 μM Compound: Top	Antiproliferative activity against human MDA-MB-231 cells after 72 hrs by XTT assay Antiproliferative activity against human MDA-MB-231 cells after 72 hrs by XTT assay	[PMID: 23237975]
MDA-MB-231	IC₅₀	<0.1 μM Compound: Topotecan	Antiproliferative activity against human MDA-MB-231 cells after 3 days by XTT assay Antiproliferative activity against human MDA-MB-231 cells after 3 days by XTT assay	[PMID: 24727241]
MDA-MB-231	IC₅₀	>500 nM Compound: Topotecan	Cytotoxicity against human MDA-MB-231 cells after 72 hrs by MTT assay Cytotoxicity against human MDA-MB-231 cells after 72 hrs by MTT assay	[PMID: 24900725]
MDA-MB-231	IC₅₀	0.102 μM Compound: 2	Cytotoxicity against human MDA-MB-231 cells after 72 hrs sulforhodamine B colorimetric assay Cytotoxicity against human MDA-MB-231 cells after 72 hrs sulforhodamine B colorimetric assay	[PMID: 25008456]
MDA-MB-231	IC₅₀	0.1 μM Compound: 2	Cytotoxicity against human MDA-MB-231 cells after 72 hrs by SRB assay Cytotoxicity against human MDA-MB-231 cells after 72 hrs by SRB assay	[PMID: 25438769]
MDA-MB-231	IC₅₀	<0.1 μM Compound: Topotecan	Antiproliferative activity against human MDA-MB-231 cells after 72 hrs by XTT assay Antiproliferative activity against human MDA-MB-231 cells after 72 hrs by XTT assay	[PMID: 26686931]
MDA-MB-231	IC₅₀	773 nM Compound: 3	Cytotoxicity against human MDA-MB-231 cells after 72 hrs by sulforhodamine B assay Cytotoxicity against human MDA-MB-231 cells after 72 hrs by sulforhodamine B assay	[PMID: 28285912]
MDA-MB-231	IC₅₀	0.77 μM Compound: 3; TPT	Cytotoxicity against human MDA-MB-231 cells after 72 hrs by SRB assay Cytotoxicity against human MDA-MB-231 cells after 72 hrs by SRB assay	[PMID: 28789891]
MDA-MB-231	IC₅₀	773 nM Compound: 3	Cytotoxicity against human MDA-MB-231 cells after 72 hrs by SRB assay Cytotoxicity against human MDA-MB-231 cells after 72 hrs by SRB assay	[PMID: 28927790]
MDA-MB-231	IC₅₀	1.898 μM Compound: Topotecan	Cytotoxicity in human MDA-MB-231 cells assessed as reduction in cell viability incubated for 48 hrs by MTT assay Cytotoxicity in human MDA-MB-231 cells assessed as reduction in cell viability incubated for 48 hrs by MTT assay	[PMID: 30227711]
MDA-MB-231	IC₅₀	101.5 nM Compound: Topotecan	Cytotoxicity against human MDA-MB-231 cells assessed as growth inhibition measured after 72 hrs by MTT assay Cytotoxicity against human MDA-MB-231 cells assessed as growth inhibition measured after 72 hrs by MTT assay	[PMID: 31881457]
MDA-MB-435	IC₅₀	0.079 μM Compound: Topotecan	Cytotoxicity against human MDA-MB-435 cells after 3 days by MTT assay Cytotoxicity against human MDA-MB-435 cells after 3 days by MTT assay	[PMID: 20202723]
MDA-MB-435	IC₅₀	<0.001 μM Compound: 2, Hycamtin	Cytotoxicity against human MDA-MB-435 cells after 72 hrs by MTT assay Cytotoxicity against human MDA-MB-435 cells after 72 hrs by MTT assay	[PMID: 20371183]
MDA-MB-435	IC₅₀	0.448 μM Compound: TPT, Hycamptin	Cytotoxicity against human MDA-MB-435 cells after 3 days by MTT assay Cytotoxicity against human MDA-MB-435 cells after 3 days by MTT assay	[PMID: 21463912]
MDA-MB-435	GI₅₀	0.034 μM Compound: TPT	Cytotoxicity against human MDA-MB-435 cells incubated for 72 hrs by MTT assay Cytotoxicity against human MDA-MB-435 cells incubated for 72 hrs by MTT assay	[PMID: 22867019]
MDA-MB-435	IC₅₀	0.917 μM Compound: TPT	Antiproliferative activity against human MDA-MB-435 cells after 3 days by MTT assay Antiproliferative activity against human MDA-MB-435 cells after 3 days by MTT assay	[PMID: 23084702]
MDA-MB-435	IC₅₀	0.4 μM Compound: TPT	Cytotoxicity against human MDA-MB-435 cells after 72 hrs by MTT assay Cytotoxicity against human MDA-MB-435 cells after 72 hrs by MTT assay	[PMID: 26226379]
MES-SA	IC₅₀	4 nM Compound: 7	Cytotoxicity against human MESSA cells after 72 hrs by alamar blue assay Cytotoxicity against human MESSA cells after 72 hrs by alamar blue assay	[PMID: 21341674]
MES-SA/Dx5	IC₅₀	33 nM Compound: 7	Cytotoxicity against human MES-SA/Dx5 cells overexpressing MDR1 after 72 hrs by alamar blue assay Cytotoxicity against human MES-SA/Dx5 cells overexpressing MDR1 after 72 hrs by alamar blue assay	[PMID: 21341674]
MGC-803	IC₅₀	0.19 μM Compound: Topotecan	Cytotoxicity in human MGC803 cells assessed as reduction in cell viability incubated for 48 hrs by MTT assay Cytotoxicity in human MGC803 cells assessed as reduction in cell viability incubated for 48 hrs by MTT assay	[PMID: 30227711]
MGC-803	IC₅₀	0.74 μM Compound: TPT	Antiproliferative activity against human MGC-803 cells assessed as reduction in cell viability measured after 72 hrs by MTT assay Antiproliferative activity against human MGC-803 cells assessed as reduction in cell viability measured after 72 hrs by MTT assay	[PMID: 34774339]
MGC-803	IC₅₀	0.74 μM Compound: TPT	Antiproliferative activity against human MGC-803 cells assessed as inhibition of cell proliferation incubated for 72 hrs by MTT assay Antiproliferative activity against human MGC-803 cells assessed as inhibition of cell proliferation incubated for 72 hrs by MTT assay	[PMID: 35728506]
MGC-803	IC₅₀	0.42 μM Compound: TPT	Antiproliferative activity against human MGC-803 cells assessed as reduction in cell viability incubated for 72 hrs by MTT assay Antiproliferative activity against human MGC-803 cells assessed as reduction in cell viability incubated for 72 hrs by MTT assay	[PMID: 37099835]
MKN-45	IC₅₀	38 nM Compound: topotecan	In Vitro cytotoxicity against human stomach cancer cell line (MKN45) In Vitro cytotoxicity against human stomach cancer cell line (MKN45)	[PMID: 11334569]
MOLT-4	IC₅₀	19 nM Compound: Topotecan	Cytotoxicity against human MOLT4 cells after 72 hrs by MTT assay Cytotoxicity against human MOLT4 cells after 72 hrs by MTT assay	[PMID: 24900725]
MRC5	GI₅₀	4.25 μM Compound: Topotecan	Cytotoxicity against human MRC5 cells after 72 hrs by XTT assay Cytotoxicity against human MRC5 cells after 72 hrs by XTT assay	[PMID: 19796956]
MRC5	IC₅₀	4.25 μM Compound: Topotecan	Antiproliferative activity against human MRC5 cells after 72 hrs by XTT assay Antiproliferative activity against human MRC5 cells after 72 hrs by XTT assay	[PMID: 26686931]
NCI/ADR-RES	GI₅₀	0.07 μM Compound: Topotecan	In vitro anti-cancer activity against MCF-7/ADR (Breast) human tumor cell line In vitro anti-cancer activity against MCF-7/ADR (Breast) human tumor cell line	[PMID: 10397491]
NCI/ADR-RES	GI₅₀	0.07 μM Compound: Topotecan	Tested in vitro for cytotoxicity against human tumor cell line MCF-7/ADR (breast) Tested in vitro for cytotoxicity against human tumor cell line MCF-7/ADR (breast)	[PMID: 10714502]
NCI-H1048	GI₅₀	14 μM Compound: Topotecan	Growth inhibition of human NCI-H1048 cells measured after 72 to 96 hrs by cell-titer glo assay Growth inhibition of human NCI-H1048 cells measured after 72 to 96 hrs by cell-titer glo assay	[PMID: 39102508]
NCI-H128	IC₅₀	31 nM Compound: topotecan	In Vitro cytotoxicity against human lung cancer cell line (H128) In Vitro cytotoxicity against human lung cancer cell line (H128)	[PMID: 11334569]
NCI-H1299	GI₅₀	>10 μM Compound: Topotecan	Antiproliferative activity against human H1299 cells after 72 hrs by XTT assay Antiproliferative activity against human H1299 cells after 72 hrs by XTT assay	[PMID: 19796956]
NCI-H1299	GI₅₀	>10 μM Compound: Topotecan	Growth inhibition of human H1299 cells after 72 hrs by XTT assay Growth inhibition of human H1299 cells after 72 hrs by XTT assay	[PMID: 22079254]
NCI-H1299	IC₅₀	6.02 μM Compound: Top	Antiproliferative activity against human H1299 cells after 72 hrs by XTT assay Antiproliferative activity against human H1299 cells after 72 hrs by XTT assay	[PMID: 23237975]
NCI-H1299	IC₅₀	6.02 μM Compound: Topotecan	Antiproliferative activity against human H1299 cells after 3 days by XTT assay Antiproliferative activity against human H1299 cells after 3 days by XTT assay	[PMID: 24727241]
NCI-H1299	IC₅₀	10.97 μM Compound: TPT	Antiproliferative activity against human NCI-H1299 cells assessed as growth inhibition after 48 hrs by MTT assay Antiproliferative activity against human NCI-H1299 cells assessed as growth inhibition after 48 hrs by MTT assay	[PMID: 24826818]
NCI-H1299	IC₅₀	4.18 μM Compound: Topotecan	Antiproliferative activity against human H1299 cells after 24 hrs by MTT assay Antiproliferative activity against human H1299 cells after 24 hrs by MTT assay	[PMID: 25147141]
NCI-H1299	IC₅₀	6.02 μM Compound: Topotecan	Antiproliferative activity against human H1299 cells after 72 hrs by XTT assay Antiproliferative activity against human H1299 cells after 72 hrs by XTT assay	[PMID: 26686931]
NCI-H460	IC₅₀	1.38 μM Compound: Topotecan	In vitro cytotoxic activity against human non small cell lung carcinoma H460 cell line In vitro cytotoxic activity against human non small cell lung carcinoma H460 cell line	[PMID: 11052801]
NCI-H460	IC₅₀	7.1 μM Compound: Topotecan	Concentration causing 50% decrease of topotecan-resistant subline (H460/TPT) cell growth over that of untreated control. Concentration causing 50% decrease of topotecan-resistant subline (H460/TPT) cell growth over that of untreated control.	[PMID: 11052801]
NCI-H460	IC₅₀	1.38 μM Compound: Topotecan	In vitro cytotoxicity against H460 a human non-small lung carcinoma cell line after 1 hour drug exposure In vitro cytotoxicity against H460 a human non-small lung carcinoma cell line after 1 hour drug exposure	[PMID: 11212094]
NCI-H460	IC₅₀	1.38 μM Compound: topotecan	Inhibition of human H460 cell growth Inhibition of human H460 cell growth	[PMID: 16913706]
NCI-H460	IC₅₀	0.008 μg/mL Compound: topotecan	Antiproliferative activity against human NCI-H460 cells after 72 hrs Antiproliferative activity against human NCI-H460 cells after 72 hrs	[PMID: 17190463]
NCI-H460	IC₅₀	1.18 μM Compound: topotecan	Cytotoxicity against human NCI-H460 cells after 1 hr Cytotoxicity against human NCI-H460 cells after 1 hr	[PMID: 18248813]
NCI-H460	IC₅₀	1.18 μM Compound: topotecan	Antiproliferative activity against human H460 cells after 1 hr of drug exposure measured after 72 hrs Antiproliferative activity against human H460 cells after 1 hr of drug exposure measured after 72 hrs	[PMID: 18424133]
NCI-H460	IC₅₀	1.18 μM Compound: topotecan	Cytotoxicity against human H460 cells Cytotoxicity against human H460 cells	[PMID: 18434153]
NCI-H460	IC₅₀	0.036 μM Compound: 3	Antitumor activity against human NCI-H460 cells by SRB method Antitumor activity against human NCI-H460 cells by SRB method	[PMID: 19541483]
NCI-H460	IC₅₀	110 nM Compound: 7	Cytotoxicity against human H460 cells after 72 hrs by alamar blue assay in presence of 40 mg/ml HSA Cytotoxicity against human H460 cells after 72 hrs by alamar blue assay in presence of 40 mg/ml HSA	[PMID: 21341674]
NCI-H460	IC₅₀	45 nM Compound: 7	Cytotoxicity against human H460 cells after 72 hrs by alamar blue assay Cytotoxicity against human H460 cells after 72 hrs by alamar blue assay	[PMID: 21341674]
NCI-H460	IC₅₀	1.38 μM Compound: topotecan	Cytotoxicity against human H460 cells assessed as stimulation of topoisomerase 1-mediated DNA cleavage Cytotoxicity against human H460 cells assessed as stimulation of topoisomerase 1-mediated DNA cleavage	[PMID: 21542600]
NCI-H460	IC₅₀	0.016 μM Compound: Topotecan	Antiproliferative activity against human NCI-H460 cells after 72 hrs by coulter counter analysis Antiproliferative activity against human NCI-H460 cells after 72 hrs by coulter counter analysis	[PMID: 21783369]
NCI-H460	IC₅₀	1.75 μM Compound: Topotecan	Antiproliferative activity against human NCI-H460 cells after 1 hr by coulter counter analysis Antiproliferative activity against human NCI-H460 cells after 1 hr by coulter counter analysis	[PMID: 21783369]
NCI-H460	IC₅₀	7.29 μM Compound: Top	Antiproliferative activity against human H460 cells after 72 hrs by XTT assay Antiproliferative activity against human H460 cells after 72 hrs by XTT assay	[PMID: 23237975]
NCI-H460	GI₅₀	44.67 nM Compound: 20	Cytotoxicity against human H460 cells after 72 hrs by MTT assay Cytotoxicity against human H460 cells after 72 hrs by MTT assay	[PMID: 24502276]
NCI-H460	GI₅₀	>1000 nM Compound: 20	Cytotoxicity against human mitoxantrone-resistant H460 cells after 72 hrs by MTT assay Cytotoxicity against human mitoxantrone-resistant H460 cells after 72 hrs by MTT assay	[PMID: 24502276]
NCI-H69	IC₅₀	15.9 nM Compound: Topotecan	Cytotoxicity measured using the H69 parental (H69/P) human small cell lung carcinoma cell line Cytotoxicity measured using the H69 parental (H69/P) human small cell lung carcinoma cell line	[PMID: 11806724]
NCI-H69	IC₅₀	62.9 nM Compound: Topotecan	Cytotoxicity measured using the drug resistant, P-glycoprotein (Pgp) expressing human small cell lung carcinoma cell line H69/LX4 Cytotoxicity measured using the drug resistant, P-glycoprotein (Pgp) expressing human small cell lung carcinoma cell line H69/LX4	[PMID: 11806724]
NCI-H69	IC₅₀	6 nM Compound: 7	Cytotoxicity against human H69 cells after 72 hrs by alamar blue assay Cytotoxicity against human H69 cells after 72 hrs by alamar blue assay	[PMID: 21341674]
OVCAR-3	GI₅₀	0.22 μM Compound: 2	Growth inhibition of human OVCAR3 cells by five-dose growth inhibition assay Growth inhibition of human OVCAR3 cells by five-dose growth inhibition assay	[PMID: 25909279]
OVCAR-8	GI₅₀	0.2 μM Compound: Topotecan	In vitro anti-cancer activity against OVCAR 8(Ovarian) human tumor cell line In vitro anti-cancer activity against OVCAR 8(Ovarian) human tumor cell line	[PMID: 10397491]
OVCAR-8	GI₅₀	0.2 μM Compound: Topotecan	Tested in vitro for cytotoxicity against human tumor cell line OVCAR8 (ovarian). Tested in vitro for cytotoxicity against human tumor cell line OVCAR8 (ovarian).	[PMID: 10714502]
P388	IC₅₀	0.04 μM Compound: Topotecan	Concentration required to inhibit cell proliferation in P388 tumor cell line Concentration required to inhibit cell proliferation in P388 tumor cell line	[PMID: 15482929]
P388	IC₅₀	>10 μM Compound: Topotecan	Inhibitory concentration against camptothecin-resistant variant of P388 cell line was determined Inhibitory concentration against camptothecin-resistant variant of P388 cell line was determined	[PMID: 15689163]
P388	IC₅₀	0.045 μM Compound: Topotecan	Inhibitory concentration against P388 cell line in mouse leukemia was determine Inhibitory concentration against P388 cell line in mouse leukemia was determine	[PMID: 15689163]
P388	IC₅₀	>10 μM Compound: topotecan	Cytotoxicity against camptothecin-resistant mouse P388 cells by MTT method Cytotoxicity against camptothecin-resistant mouse P388 cells by MTT method	[PMID: 18771930]
P388	IC₅₀	0.045 μM Compound: topotecan	Cytotoxicity against mouse P388 cells by MTT method Cytotoxicity against mouse P388 cells by MTT method	[PMID: 18771930]
P388	IC₅₀	0.045 μM Compound: Topotecan	Cytotoxicity against mouse P388 cells after MTT assay Cytotoxicity against mouse P388 cells after MTT assay	[PMID: 18829334]
P388	IC₅₀	0.045 μM Compound: Topotecan	Cytotoxicity against mouse P388 cells by MTT method Cytotoxicity against mouse P388 cells by MTT method	[PMID: 19012996]
P388CPT45	IC₅₀	>10 μM Compound: Topotecan	Cytotoxicity against camptothecin-resistant and TOP1 deficient mouse P388/CPT45 cells after MTT assay Cytotoxicity against camptothecin-resistant and TOP1 deficient mouse P388/CPT45 cells after MTT assay	[PMID: 18829334]
Panel (56 tumour cell lines)	IC₅₀	0.16 μM Compound: Topotecan	Tested in vitro for cytotoxicity against 56 human tumor cell lines Tested in vitro for cytotoxicity against 56 human tumor cell lines	[PMID: 10714502]
PC-3	IC₅₀	3.99 μM Compound: 2, TPT	Cytotoxicity against human PC3 cells by MTT assay Cytotoxicity against human PC3 cells by MTT assay	[PMID: 19056266]
PC-3	GI₅₀	1.3 μM Compound: 3, TPT	Cytotoxicity against p53-deficient human PC3 cells after 48 hrs by SRB assay Cytotoxicity against p53-deficient human PC3 cells after 48 hrs by SRB assay	[PMID: 19715319]
PC-3	IC₅₀	2 μM Compound: 3, TPT	Cytotoxicity against p53-deficient human PC3 cells after 48 hrs by SRB assay Cytotoxicity against p53-deficient human PC3 cells after 48 hrs by SRB assay	[PMID: 19715319]
PC-3	IC₅₀	1 μM Compound: Topotecan	Antiproliferative activity against human PC3 cells by [3H]thymidine incorporation assay Antiproliferative activity against human PC3 cells by [3H]thymidine incorporation assay	[PMID: 20932758]
PC-3	IC₅₀	45 nM Compound: 7	Cytotoxicity against human PC3 cells after 72 hrs by alamar blue assay Cytotoxicity against human PC3 cells after 72 hrs by alamar blue assay	[PMID: 21341674]
PC-3	IC₅₀	0.185 μM Compound: 4	Cytotoxicity against human PC3 cells expressing alpha5beta3 integrin assessed as cell survival after 72 hrs by SRB assay Cytotoxicity against human PC3 cells expressing alpha5beta3 integrin assessed as cell survival after 72 hrs by SRB assay	[PMID: 22959246]
PC-3	IC₅₀	62 nM Compound: Topotecan	Cytotoxicity against human PC3 cells after 72 hrs by MTT assay Cytotoxicity against human PC3 cells after 72 hrs by MTT assay	[PMID: 24900725]
PC-3	IC₅₀	<4 μM Compound: topotecan	Cytotoxicity against human PC3 cells assessed as inhibition of cell growth Cytotoxicity against human PC3 cells assessed as inhibition of cell growth	[PMID: 25461317]
PC-3	IC₅₀	9.35 μM Compound: Topotecan	Antiproliferative activity against human PC3 cells after 72 hrs by XTT assay Antiproliferative activity against human PC3 cells after 72 hrs by XTT assay	[PMID: 26686931]
PC-3	IC₅₀	160 nM Compound: TPT	Antiproliferative activity measured against PC-3 human prostate adenocarcinoma Antiproliferative activity measured against PC-3 human prostate adenocarcinoma	[PMID: 9876111]
QGY-7703	IC₅₀	11.864 μM Compound: Topotecan	Cytotoxicity in human QGY7703 cells assessed as reduction in cell viability incubated for 48 hrs by MTT assay Cytotoxicity in human QGY7703 cells assessed as reduction in cell viability incubated for 48 hrs by MTT assay	[PMID: 30227711]
RKO	IC₅₀	0.42 μM Compound: TPT	Antiproliferative activity against human RKO cells assessed as reduction in cell viability incubated for 72 hrs by MTT assay Antiproliferative activity against human RKO cells assessed as reduction in cell viability incubated for 72 hrs by MTT assay	[PMID: 37099835]
RPMI 8402	IC₅₀	>10 μM Compound: Topotecan	Cytotoxicity using camptothecin-resistant variant of RPM18402 (CPT-K5) possessing functional, but mutant TOP-1 Cytotoxicity using camptothecin-resistant variant of RPM18402 (CPT-K5) possessing functional, but mutant TOP-1	[PMID: 12392745]
RPMI 8402	IC₅₀	0.012 μM Compound: Topotecan	Cytotoxicity against human lymphoblast tumor cell line RPM18402 Cytotoxicity against human lymphoblast tumor cell line RPM18402	[PMID: 12392745]
RPMI 8402	IC₅₀	0.012 μM Compound: Topotecan	Cytotoxic activity against human lymphoblast tumor cell line RPMI8402 after 4 days of treatment Cytotoxic activity against human lymphoblast tumor cell line RPMI8402 after 4 days of treatment	[PMID: 12747798]
RPMI 8402	IC₅₀	>10 μM Compound: Topotecan	Concentration required to inhibit cell proliferation in CPT-K5 tumor cell line; camptothecin resistant Concentration required to inhibit cell proliferation in CPT-K5 tumor cell line; camptothecin resistant	[PMID: 15482929]
RPMI 8402	IC₅₀	0.02 μM Compound: Topotecan	Concentration required to inhibit cell proliferation in RPM18402 tumor cell line Concentration required to inhibit cell proliferation in RPM18402 tumor cell line	[PMID: 15482929]
RPMI 8402	IC₅₀	>10 μM Compound: Topotecan	Cytotoxicity against camptothecin-resistant RPMI 8402 Cytotoxicity against camptothecin-resistant RPMI 8402	[PMID: 15689163]
RPMI 8402	IC₅₀	0.021 μM Compound: Topotecan	Inhibitory concentration against lymphoblast RPMI 8402 cell line was determined Inhibitory concentration against lymphoblast RPMI 8402 cell line was determined	[PMID: 15689163]
RPMI 8402	IC₅₀	0.21 μM Compound: topotecan	Cytotoxicity against human RPMI8402 cells by MTT method Cytotoxicity against human RPMI8402 cells by MTT method	[PMID: 18771930]
RPMI 8402	IC₅₀	0.021 μM Compound: Topotecan	Cytotoxicity against human RPMI8402 cells after MTT assay Cytotoxicity against human RPMI8402 cells after MTT assay	[PMID: 18829334]
RPMI-8226	IC₅₀	0.021 μM Compound: Topotecan	Cytotoxicity against human RPMI8226 cells by MTT method Cytotoxicity against human RPMI8226 cells by MTT method	[PMID: 19012996]
SAOS-2	IC₅₀	<170 nM Compound: Topotecan	TP_TRANSPORTER: drug resistance(Imatinib mesylate) in BCRP-expressing SaoS2 cells TP_TRANSPORTER: drug resistance(Imatinib mesylate) in BCRP-expressing SaoS2 cells	[PMID: 15059881]
SF-268	GI₅₀	0.08 μM Compound: Topotecan	In vitro anti-cancer activity against SF 268(CNS) human tumor cell line In vitro anti-cancer activity against SF 268(CNS) human tumor cell line	[PMID: 10397491]
SF-268	GI₅₀	0.08 μM Compound: Topotecan	Tested in vitro for cytotoxicity against human tumor cell line SF-268 (CNS). Tested in vitro for cytotoxicity against human tumor cell line SF-268 (CNS).	[PMID: 10714502]
SF-539	GI₅₀	0.01 μM Compound: 2	Growth inhibition of human SF539 cells by five-dose growth inhibition assay Growth inhibition of human SF539 cells by five-dose growth inhibition assay	[PMID: 25909279]
Sf9	IC₅₀	0.021 μM Compound: Topotecan	Poison activity at recombinant human TOP1 expressed in baculovirus infected Sf9 insect cells assessed as decrease in relaxed supercoiled pBS(SK+) DNA mobility measured after 30 mins by ethidium bromide staining based agarose gel electrophoresis Poison activity at recombinant human TOP1 expressed in baculovirus infected Sf9 insect cells assessed as decrease in relaxed supercoiled pBS(SK+) DNA mobility measured after 30 mins by ethidium bromide staining based agarose gel electrophoresis	[PMID: 30897325]
SGC-7901	IC₅₀	>10 μM Compound: Topotecan	Cytotoxicity in human SGC7901 cells assessed as reduction in cell viability incubated for 48 hrs by MTT assay Cytotoxicity in human SGC7901 cells assessed as reduction in cell viability incubated for 48 hrs by MTT assay	[PMID: 30227711]
SGC-7901	IC₅₀	4.17 μM Compound: TPT	Antiproliferative activity against human SGC-7901 cells assessed as reduction in cell viability measured after 72 hrs by MTT assay Antiproliferative activity against human SGC-7901 cells assessed as reduction in cell viability measured after 72 hrs by MTT assay	[PMID: 34774339]
SGC-7901	IC₅₀	4.17 μM Compound: TPT	Antiproliferative activity against human SGC-7901 cells assessed as inhibition of cell proliferation incubated for 72 hrs by MTT assay Antiproliferative activity against human SGC-7901 cells assessed as inhibition of cell proliferation incubated for 72 hrs by MTT assay	[PMID: 35728506]
SGC-7901	IC₅₀	0.69 μM Compound: TPT	Antiproliferative activity against human SGC-7901 cells assessed as reduction in cell viability incubated for 72 hrs by MTT assay Antiproliferative activity against human SGC-7901 cells assessed as reduction in cell viability incubated for 72 hrs by MTT assay	[PMID: 37099835]
SK-BR-3	IC₅₀	26 nM Compound: topotecan	In Vitro cytotoxicity against human breast cancer cell line (SK-BR-3) In Vitro cytotoxicity against human breast cancer cell line (SK-BR-3)	[PMID: 11334569]
SK-BR-3	IC₅₀	8.91 μM Compound: Top	Antiproliferative activity against human SKBR3 cells after 72 hrs by XTT assay Antiproliferative activity against human SKBR3 cells after 72 hrs by XTT assay	[PMID: 23237975]
SK-MEL-2	IC₅₀	140 nM Compound: 7	Cytotoxicity against human SK-MEL-2 cells after 72 hrs by alamar blue assay Cytotoxicity against human SK-MEL-2 cells after 72 hrs by alamar blue assay	[PMID: 21341674]
SK-N-SH	IC₅₀	0.093 μM Compound: Topotecan	Cytotoxicity in human SK-N-SH cells assessed as reduction in cell viability incubated for 48 hrs by MTT assay Cytotoxicity in human SK-N-SH cells assessed as reduction in cell viability incubated for 48 hrs by MTT assay	[PMID: 30227711]
SK-OV-3	IC₅₀	48 nM Compound: topotecan	In Vitro cytotoxicity against human ovarian cancer cell line (SK-OV-3) In Vitro cytotoxicity against human ovarian cancer cell line (SK-OV-3)	[PMID: 11334569]
SK-OV-3	IC₅₀	44 nM Compound: Topotecan	Cytotoxicity was determined in vitro in SK-OV-3 cells (ovarian) of human tumor cell lines by using MTT assay Cytotoxicity was determined in vitro in SK-OV-3 cells (ovarian) of human tumor cell lines by using MTT assay	[PMID: 7853331]
SK-OV-3	IC₅₀	44 nM Compound: 3	Human tumor cell cytotoxicity assay was performed using MTT (SK-OV3 cell line ) Human tumor cell cytotoxicity assay was performed using MTT (SK-OV3 cell line )	[PMID: 8576914]
SK-VLB	IC₅₀	149 nM Compound: Topotecan	Cytotoxicity was determined in vitro in SKVLB cells(ovarian with upregulated MDRp-glycoprotein) of human tumor cell lines by using MTT assay Cytotoxicity was determined in vitro in SKVLB cells(ovarian with upregulated MDRp-glycoprotein) of human tumor cell lines by using MTT assay	[PMID: 7853331]
SK-VLB	IC₅₀	150 nM Compound: 3	Human tumor cell cytotoxicity assay was performed using MTT (SKVLB cell line ) Human tumor cell cytotoxicity assay was performed using MTT (SKVLB cell line )	[PMID: 8576914]
SMMC-7721	IC₅₀	11.627 μM Compound: Topotecan	Cytotoxicity in human SMMC7721 cells assessed as reduction in cell viability incubated for 48 hrs by MTT assay Cytotoxicity in human SMMC7721 cells assessed as reduction in cell viability incubated for 48 hrs by MTT assay	[PMID: 30227711]
SN12C	GI₅₀	0.02 μM Compound: 2	Growth inhibition of human SN12C cells by five-dose growth inhibition assay Growth inhibition of human SN12C cells by five-dose growth inhibition assay	[PMID: 25909279]
SW480	IC₅₀	0.09 μM Compound: TPT	Antiproliferative activity against human SW480 cells assessed as reduction in cell viability incubated for 72 hrs by MTT assay Antiproliferative activity against human SW480 cells assessed as reduction in cell viability incubated for 72 hrs by MTT assay	[PMID: 37099835]
SW480	IC₅₀	9.65 μM Compound: Topotecan	Inhibition of DNA topoisomerase 1 in Homo sapiens (human) SW480 cells Inhibition of DNA topoisomerase 1 in Homo sapiens (human) SW480 cells	10.1007/s00044-009-9233-5
SW-620	IC₅₀	3.2 nM Compound: Topotecan	Cytotoxic potentiation of Topotecan (TP) by the compound in human colon carcinoma SW620 cell line Cytotoxic potentiation of Topotecan (TP) by the compound in human colon carcinoma SW620 cell line	[PMID: 12408707]
SW-620	IC₅₀	>500 nM Compound: 2	Antiproliferative activity against human SW-620 cells assessed as inhibition of cell growth incubated for 72 hrs by SRB assay Antiproliferative activity against human SW-620 cells assessed as inhibition of cell growth incubated for 72 hrs by SRB assay	[PMID: 35932565]
T47D	IC₅₀	104 nM Compound: Topotecan	Cytotoxicity was determined in vitro in T47D cells(breast) of human tumor cell lines by using MTT assay Cytotoxicity was determined in vitro in T47D cells(breast) of human tumor cell lines by using MTT assay	[PMID: 7853331]
THP-1	IC₅₀	1.5 μM Compound: 3, TPT	Cytotoxicity against human THP1 cells expressing p53 mutant after 48 hrs by SRB assay Cytotoxicity against human THP1 cells expressing p53 mutant after 48 hrs by SRB assay	[PMID: 19715319]
U-251	EC₅₀	181 nM Compound: Topotecan	Inhibition of iron chelator DFO-induced HIF1 activation in human U251 cells Inhibition of iron chelator DFO-induced HIF1 activation in human U251 cells	[PMID: 15620241]
U-251	EC₅₀	71.3 nM Compound: Topotecan	Inhibition of hypoxia-induced HIF1 activation in human U251 cells Inhibition of hypoxia-induced HIF1 activation in human U251 cells	[PMID: 15620241]
U-251	IC₅₀	>3 μM Compound: Topotecan	Inhibition of HIF1alpha in human U251 cells under normoxic condition by luciferase reporter gene assay Inhibition of HIF1alpha in human U251 cells under normoxic condition by luciferase reporter gene assay	[PMID: 20932758]
U-251	IC₅₀	0.06 μM Compound: Topotecan	Inhibition of HIF1alpha in human U251 cells under hypoxic condition by luciferase reporter gene assay Inhibition of HIF1alpha in human U251 cells under hypoxic condition by luciferase reporter gene assay	[PMID: 20932758]
U-251	IC₅₀	0.5 μM Compound: Topotecan	Antiproliferative activity against human U251 cells by [3H]thymidine incorporation assay Antiproliferative activity against human U251 cells by [3H]thymidine incorporation assay	[PMID: 20932758]
U-251	EC₅₀	54 nM Compound: 4b, NSC-609699, hycamtin	Inhibition of topoisomerase-1 in human U251 cells assessed as inhibition of hypoxia-induced HIF-1alpha accumulation in nuclear extract after 6 to 24 hrs by immunoblot analysis Inhibition of topoisomerase-1 in human U251 cells assessed as inhibition of hypoxia-induced HIF-1alpha accumulation in nuclear extract after 6 to 24 hrs by immunoblot analysis	[PMID: 22305612]
U-251	EC₅₀	71.3 nM Compound: 4b, NSC-609699, hycamtin	Inhibition of topoisomerase-1 in human U251 cells assessed as inhibition of HIF-1-mediated hypoxia-induced VEGF expression after 24 hrs by luciferase reporter gene assay Inhibition of topoisomerase-1 in human U251 cells assessed as inhibition of HIF-1-mediated hypoxia-induced VEGF expression after 24 hrs by luciferase reporter gene assay	[PMID: 22305612]
U-251	IC₅₀	0.37 μM Compound: Topotecan	Antiproliferative activity against human U-251 cells assessed as inhibition of cell growth measured after 72 hrs by CCK-8 assay Antiproliferative activity against human U-251 cells assessed as inhibition of cell growth measured after 72 hrs by CCK-8 assay	[PMID: 34537445]
U-251	EC₅₀	>20 μM Compound: 6, TPT	Effect on basal transcription in human U251 cells co-transfected with pGL3 incubated for 24 hrs by luciferase reporter gene assay Effect on basal transcription in human U251 cells co-transfected with pGL3 incubated for 24 hrs by luciferase reporter gene assay	10.1039/C4MD00111G
U-251	EC₅₀	0.012 μM Compound: 6, TPT	Inhibition of human HIF1alpha-mediated transcription expressed in human U251 cells co-transfected with pGL2-TK-HRE incubated for 24 hrs by luciferase reporter gene assay Inhibition of human HIF1alpha-mediated transcription expressed in human U251 cells co-transfected with pGL2-TK-HRE incubated for 24 hrs by luciferase reporter gene assay	10.1039/C4MD00111G
U-87MG ATCC	IC₅₀	0.16 μM Compound: TPT	Antiproliferative activity against human U87 cells assessed as growth inhibition after 48 hrs by MTT assay Antiproliferative activity against human U87 cells assessed as growth inhibition after 48 hrs by MTT assay	[PMID: 24826818]
U-87MG ATCC	IC₅₀	0.06 μM Compound: Topotecan	Antiproliferative activity against human U-87 MG cells assessed as inhibition of cell growth measured after 72 hrs by CCK-8 assay Antiproliferative activity against human U-87 MG cells assessed as inhibition of cell growth measured after 72 hrs by CCK-8 assay	[PMID: 34537445]
U-937	IC₅₀	1.1 μM Compound: 3, TPT	Cytotoxicity against human U937 cells expressing p53 mutant after 48 hrs by SRB assay Cytotoxicity against human U937 cells expressing p53 mutant after 48 hrs by SRB assay	[PMID: 19715319]
UACC-62	GI₅₀	0.03 μM Compound: Topotecan	In vitro anti-cancer activity against UACC 62(Melanoma) human tumor cell line In vitro anti-cancer activity against UACC 62(Melanoma) human tumor cell line	[PMID: 10397491]
UACC-62	GI₅₀	0.03 μM Compound: Topotecan	Tested in vitro for cytotoxicity against human tumor cell line UACC 62 (melanoma) Tested in vitro for cytotoxicity against human tumor cell line UACC 62 (melanoma)	[PMID: 10714502]
UACC-62	GI₅₀	0.01 μM Compound: 2	Growth inhibition of human UACC62 cells by five-dose growth inhibition assay Growth inhibition of human UACC62 cells by five-dose growth inhibition assay	[PMID: 25909279]
WiDr	IC₅₀	56 nM Compound: topotecan	In Vitro cytotoxicity against human colon cancer cell line (WiDr) In Vitro cytotoxicity against human colon cancer cell line (WiDr)	[PMID: 11334569]
WISH	IC₅₀	1.3 μM Compound: Topotecan	Cytotoxicity against human WISH cells after 96 hrs by MTT assay Cytotoxicity against human WISH cells after 96 hrs by MTT assay	[PMID: 16792409]

In Vitro

Topotecan obviously inhibits proliferation of human glioma cells and glioma stem cells (GSCs) in a dose- and time-dependent manner^[1].
Topotecan (0-40 μM) obviously inhibits the cell viability compared with the control groups, in a dose-dependent manner^[1].
Topotecan shows anti-proliferation activity against U251, U87, GSCs-U251 and GSCs-U87 cells, with IC₅₀ values of 2.73±0.25, 2.95±0.23, 5.46±0.41, and 5.95±0.24 μM, respectively^[1].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

In Vivo

NUB-7 metastatic model, the animals belonging to all the 4 groups are sacrificed after 14 days treatment. Compared with the control, Low dose metronomic (LDM) Topotecan (TP) and TP+Pazopanib (PZ) liver weights are significantly lower in TP+PZ-treated animals, compared with PZ. Microscopic tumors are visible in the livers of mice belonging to all the groups except TP+PZ confirming the ability of TP+PZ to control liver metastasis^[2].
Topotecan (0.5, 1.0, and 1.5 mg/kg; Orally, daily) causes greater reduction in microvascular density in an ovarian cancer model, but the mice treated with 1.5 mg/kg daily, oral Topotecan show decreased food intake, and a lesser antitumor effect^[2].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

Clinical Trial

NCT Number	Sponsor	Condition	Start Date	Phase A549
NCT01329991	Plexxikon\|		2011-05	PHASE1

Chemical Information

CAS No. 123948-87-8
Appearance Solid
Molecular Weight 421.45
Formula C₂₃H₂₃N₃O₅
Color Light yellow to yellow
SMILES

O=C1[C@](O)(CC)C2=C(CO1)C(N3CC4=CC5=C(CN(C)C)C(O)=CC=C5N=C4C3=C2)=O
Synonyms

SKF 104864A; NSC 609669
Shipping

Room temperature in continental US; may vary elsewhere.

Storage

Powder	-20°C	3 years
	4°C	2 years
In solvent	-80°C	6 months
	-20°C	1 month

Publications (38)

All In Vivo Efficacy StudyFlow CytometryCell Proliferation/Viability AssayIFWB

Sort by:

Journal Impact Factor

Cancer Res

Topoisomerase 1 Inhibition in MYC-Driven Cancer Promotes Aberrant R-Loop Accumulation to Induce Synthetic Lethality. [Abstract]

2023 Dec 15;83(24):4015-4029. PMID: 37987734

Topotecan purchased from MedChemExpress. Usage Cited in: Cancer Res. 2023 Dec 15;83(24):4015-4029. [Abstract]

Topotecan hydrochloride (10 mg/kg; ip). Tumor weights from 10A.PM xenografts after Topotecan treatment.
Nat Commun

Selective targeting of genome amplifications and repeat elements by CRISPR-Cas9 nickases to promote cancer cell death. [Abstract]

2025 Jun 2;16(1):5126. PMID: 40456709
Nat Commun

Genotoxic stress-triggered β-catenin/JDP2/PRMT5 complex facilitates reestablishing glutathione homeostasis. [Abstract]

2019 Aug 21;10(1):3761. PMID: 31434880

Topotecan purchased from MedChemExpress. Usage Cited in: Nat Commun. 2019 Aug 21;10(1):3761. [Abstract]

Topotecan (10 mg/kg; Intraperitoneal injection). Representative images and the apoptotic rate the indicated chemotherapy-treated xenograft tumors.

Topotecan purchased from MedChemExpress. Usage Cited in: Nat Commun. 2019 Aug 21;10(1):3761. [Abstract]

Topotecan (10 mg/kg; Intraperitoneal injection). IB analysis of the level of cleaved-caspase 3 and cleaved-PARP1 in the indicated chemotherapy-treated xenograft tumors. GAPDH served as the loading control.
J Extracell Vesicles

Analysis of extracellular vesicle DNA at the single-vesicle level by nano-flow cytometry. [Abstract]

2022 Apr;11(4):e12206. PMID: 35373518

Topotecan purchased from MedChemExpress. Usage Cited in: J Extracell Vesicles. 2022 Apr;11(4):e12206. [Abstract]

Topotecan hydrochloride (20 μM; 48 h). Bivariate dot‐plots of SYTO 16 fluorescence versus EV size of EVs for EV preparations from HCT‐15 cells treated with DMSO control (i), etoposide (ii), SN‐38 (iii) or topotecan (iv).
J Exp Clin Cancer Res

Arsenic trioxide reverses the chemoresistance in hepatocellular carcinoma: a targeted intervention of 14-3-3η/NF-κB feedback loop. [Abstract]

2018 Dec 20;37(1):321. PMID: 30572915
MedComm (2020)

KSQ-4279, an Inhibitor of Ubiquitin Specific Peptidase 1, Enhanced the Chemotherapeutic Efficacy in ABCB1/ABCG2/ABCC1-Mediated Multidrug Resistant Cancers. [Abstract]

2025 Nov 29;6(12):e70517. PMID: 41328326
Cell Rep Med

CAN-Scan: A multi-omic phenotype-driven precision oncology platform identifies prognostic biomarkers of therapy response for colorectal cancer. [Abstract]

2025 Apr 2:102053. PMID: 40187357
Pharmacol Res

Time-dependent proteomics and drug response in expanding cancer cells. [Abstract]

2024 May 9:204:107208. PMID: 38729587
Cell Death Dis

Transcription factor Sp1 transcriptionally enhances GSDME expression for pyroptosis. [Abstract]

2024 Jan 18;15(1):66. PMID: 38238307
Cell Commun Signal

BI-2865, a pan-KRAS inhibitor, reverses the P-glycoprotein induced multidrug resistance in vitro and in vivo. [Abstract]

2024 Jun 13;22(1):325. PMID: 38872211
Acta Pharmacol Sin

Osimertinib successfully combats EGFR-negative glioblastoma cells by inhibiting the MAPK pathway. [Abstract]

2021 Jan;42(1):108-114. PMID: 32398685
Cancer Immunol Res

Discovery of podofilox as a potent cGAMP-STING signaling enhancer with antitumor activity. [Abstract]

2023 May 3;11(5):583-599. PMID: 36921097
NPJ Precis Oncol

Targeting the DYRK1A kinase prevents cancer progression and metastasis and promotes cancer cells response to G1/S targeting chemotherapy drugs. [Abstract]

2024 Jun 5;8(1):128. PMID: 38839871

Topotecan purchased from MedChemExpress. Usage Cited in: NPJ Precis Oncol. 2024 Jun 5;8(1):128. [Abstract]

Topotecan hydrochloride (0.0001-100 μM; 48 h). Dose-response curves after various concentrations of chemotherapeutic drugs in DYRK1A-KOs and NT-KOs for HCT-116 cell.
J Transl Med

DB-1314, a novel DLL3-targeting ADC with DNA topoisomerase I inhibitor, exhibits promising safety profile and therapeutic efficacy in preclinical small cell lung cancer models. [Abstract]

2024 Aug 14;22(1):766. PMID: 39143619
Cell Rep

Structural basis for the reversal of human MRP4-mediated multidrug resistance by lapatinib. [Abstract]

2025 Mar 25;44(4):115466. PMID: 40138312
Cell Rep

miR-449a/miR-340 reprogram cell identity and metabolism in fusion-negative rhabdomyosarcoma. [Abstract]

2025 Jan 11;44(1):115171. PMID: 39799567
Eur J Med Chem

Innovative medicinal chemistry strategies for enhancing drug solubility. [Abstract]

2024 Dec 5:279:116842. PMID: 39260319
Biochem Pharmacol

Tazemetostat synergistically combats multidrug resistance by the unique triple inhibition of ABCB1, ABCC1, and ABCG2 efflux transporters in vitro and ex vivo. [Abstract]

2023 Oct:216:115769. PMID: 37634597
Pharmaceutics

Encorafenib Acts as a Dual-Activity Chemosensitizer through Its Inhibitory Effect on ABCC1 Transporter In Vitro and Ex Vivo. [Abstract]

2022 Nov 24;14(12):2595. PMID: 36559089
Int J Mol Sci

Inhibition of ABCG2 by SCO-101 Enhances Chemotherapy Efficacy in Cancer. [Abstract]

2025 Apr 17;26(8):3790. PMID: 40332396
Cell Rep Methods

RECOVER identifies synergistic drug combinations in vitro through sequential model optimization. [Abstract]

2023 Oct 23;3(10):100599. PMID: 37797618
J Biomed Inform

From Centralized to Ad-Hoc Knowledge Base Construction for Hypotheses Generation. [Abstract]

2023 Jun:142:104383. PMID: 37196989
Cancers (Basel)

Targeted Disruption of E6/p53 Binding Exerts Broad Activity and Synergism with Paclitaxel and Topotecan against HPV-Transformed Cancer Cells. [Abstract]

2021 Dec 31;14(1):193. PMID: 35008354
J Cell Mol Med

Inactivation of CDK12 Enhances Mitochondrial Efficiency to Suppress DNA Damage. [Abstract]

2026 Apr;30(7):e71101. PMID: 41896195
J Mol Med (Berl)

Combination of PARP inhibitor and temozolomide to suppress chordoma progression. [Abstract]

2019 Aug;97(8):1183-1193. PMID: 31201471
Sci Rep

Drug-induced PD-L1 expression and cell stress response in breast cancer cells can be balanced by drug combination. [Abstract]

2019 Oct 22;9(1):15099. PMID: 31641154
J Virol

Cellular DNA Topoisomerases Are Required for the Synthesis of Hepatitis B Virus Covalently Closed Circular DNA. [Abstract]

2019 May 15;93(11):e02230-18. PMID: 30867306
Bioengineering (Basel)

Precision Oncology for High-Grade Gliomas: A Tumor Organoid Model for Adjuvant Treatment Selection. [Abstract]

2025 Oct 19;12(10):1121. PMID: 41155119
J Nat Prod

Ingenane Diterpenoids from Euphorbia peplus as Potential New CHK1 Inhibitors That Sensitize Cancer Cells to Chemotherapy. [Abstract]

2025 Mar 28;88(3):688-705. PMID: 40056138
J Immunol

Identification of RPL15 60S Ribosomal Protein as a Novel Topotecan Target Protein That Correlates with DAMP Secretion and Antitumor Immune Activation. [Abstract]

2022 Jul 1;209(1):171-179. PMID: 35725272
Phytochemistry

Spectanoids A-H: Eight undescribed sesterterpenoids from Aspergillus spectabilis. [Abstract]

2021 Nov:191:112910. PMID: 34481345
FASEB Bioadv

Effect of static magnetic field on DNA synthesis: The interplay between DNA chirality and magnetic field left-right asymmetry. [Abstract]

2020 Mar 7;2(4):254-263. PMID: 32259051
bioRxiv

2026 Mar 13.
bioRxiv

2025 Sep 21.
Indiana University Indianapolis

2025.
bioRxiv

Rebalancing Viral and Immune Damage versus Tissue Repair Prevents Death from Lethal Influenza Infection. [Abstract]

2024 Jul 7:2024.07.04.601620. PMID: 39372755
bioRxiv

2023 Apr 14.
Universitat Autònoma de Barcelona

2022 Aug.

Solvent & Solubility

In Vitro:

DMSO : 100 mg/mL (237.28 mM; Need ultrasonic; Hygroscopic DMSO has a significant impact on the solubility of product, please use newly opened DMSO)

View the Complete Stock Solution Preparation Table

Preparing Stock Solutions

View the Complete Stock Solution Preparation Table

Concentration Solvent Mass

1 mg

5 mg

10 mg

Concentration

Solvent

Mass

1 mM

2.3728 mL

11.8638 mL

23.7276 mL

5 mM

0.4746 mL

2.3728 mL

4.7455 mL

10 mM

0.2373 mL

1.1864 mL

2.3728 mL

Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.

Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month. When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.

Molarity Calculator

Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

Mass Mass

Concentration Concentration

Volume Volume

Molecular Weight Molecular Weight

Dilution Calculator

Concentration _(start) × Volume _(start) = Concentration _(final) × Volume _(final)

Concentration _(start) Concentration _(start)

Volume _(start) Volume _(start)

Concentration _(final) Concentration _(final)

Volume _(final) Volume _(final)

In Vivo:

Select the appropriate dissolution method based on your experimental animal and administration route.

Stock Solution Working Solution

For the following dissolution methods, please ensure to first prepare a clear stock solution using an In Vitro approach and then sequentially add co-solvents:
To ensure reliable experimental results, the clarified stock solution can be appropriately stored based on storage conditions. As for the working solution for In Vivo experiments, it is recommended to prepare freshly and use it on the same day.
The percentages shown for the solvents indicate their volumetric ratio in the final prepared solution. If precipitation or phase separation occurs during preparation, heat and/or sonication can be used to aid dissolution.

Protocol 1

Add each solvent one by one: 10% DMSO 40% PEG300 5% Tween-80 45% Saline

Solubility: 2.5 mg/mL (5.93 mM); Clear solution; Need ultrasonic

This protocol yields a clear solution of 2.5 mg/mL.

Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (25.0 mg/mL) to 400 μL PEG300, and mix evenly; then add 50 μL Tween-80 and mix evenly; then add 450 μL Saline to adjust the volume to 1 mL.

Protocol 2

Add each solvent one by one: 10% DMSO 90% (20% SBE-β-CD in Saline)

Solubility: 2.5 mg/mL (5.93 mM); Clear solution; Need ultrasonic

This protocol yields a clear solution of 2.5 mg/mL.

Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (25.0 mg/mL) to 900 μL 20% SBE-β-CD in Saline, and mix evenly.

Protocol 3

Add each solvent one by one: 10% DMSO 90% Corn Oil

Solubility: ≥ 2.5 mg/mL (5.93 mM); Clear solution

This protocol yields a clear solution of ≥ 2.5 mg/mL (saturation unknown). If the continuous dosing period exceeds half a month, please choose this protocol carefully.

Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (25.0 mg/mL) to 900 μL Corn oil, and mix evenly.

In Vivo Dissolution Calculator

Please enter the basic information of animal experiments:

Dosage Dosage
mg/kg
Animal Weight (Per Animal) Animal Weight (Per Animal)
g
Dosing Volume (Per Animal) Dosing Volume (Per Animal)
μL
Number of Animals Number of Animals

Recommended: Prepare an additional quantity of animals to account for potential losses during experiments.

Recommended: Prepare an additional quantity of animals to account for potential losses during experiments.

Please enter your animal formula composition:

%
DMSO +

Recommended: Keep the proportion of DMSO in working solution below 2% if your animal is weak.
%
+
+
%
Tween-80 + +
%
Saline +

The co-solvents required include: DMSO, . All of co-solvents are available by MedChemExpress (MCE). , Tween 80. All of co-solvents are available by MedChemExpress (MCE).

Working solution concentration: 0.22 mg/mL

Protocol

Cell Assay^[1]

The U251, U87, GSCs-U251 and GSCs-U87 cells are seeded at a density of 2×10⁴ cells per well in 96-well plates separately, and incubated for 24 h. Cells are administered with Shikonin and Topotecan (0.02, 0.2, 2, 20, 40 μM). After the treatment, 10 μL of cell counting kit-8 (CCK-8) is added into each well for additional 1-hour incubation at 37°C. The optical density (OD) is read with a microplate reader at 450 nm^[1].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

Animal Administration^[2]

Mice^[2]
For subcutaneous xenograft studies, we used SK-N-BE, SH-SY5Y, KHOS, and RH30. 1×10⁶ cells are implanted subcutaneously into the inguinal fat pad of each of nonobese diabetic/severe combined immune deficient (NOD/SCID) mice. When tumors reached 0.5 cm in diameter, the animals are randomized into 4 groups and treated daily by oral gavage. The animals are grouped as: Control group, LDM Topotecan group or LDM TP (1 mg/kg Topotecan), Pazopanib group or PZ (150 mg/kg Pazopanib) and combination group or TP+PZ (1 mg/kg Topotecan+150 mg/kg Pazopanib). To compare pulse Topotecan with LDM TP in KHOS osteosarcoma model, PZ is replaced by weekly oral dose of pulse Topotecan (SKF104864) or Pulse TP (15 mg/kg Topotecan (SKF104864)). The criteria for endpoint are tumor sizes exceeding 2.0 cm in diameter or animals showing signs of morbidity. The tumor sizes are measured on a daily basis until the endpoint or sacrifice. The long (D) and short diameters (d) are measured with calipers. Tumor volume (cm³) is calculated as V=0.5×D×d². When the endpoint is reached or at the end of the treatment, the animals are sacrificed by cervical dislocation.

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

Purity & Documentation

Select Batch:

Purity: 99.98%

Assay: 99.98%

ee.: 99.98%

Data Sheet (283 KB)
SDS (396 KB)
- English - EN (396 KB)
- Français - FR (396 KB)
- Deutsch - DE (396 KB)
- Norwegian - NO (396 KB)
- Español - ES (396 KB)
- Swedish - SV (396 KB)
- Italian - IT (396 KB)
- Portuguese - PT (396 KB)
COA (2659 KB)
Elemental Analysis Report (2659 KB)
HNMR (2659 KB)
CNMR (2659 KB)
RP-HPLC (2659 KB)
NP-HPLC (2659 KB)
MS (2659 KB)
LCMS (2659 KB)
IR (2659 KB)
GC (2659 KB)
OR (2659 KB)
SDS-PAGE (2659 KB)
SEC-HPLC (2659 KB)
Other Report (2659 KB)
Handling Instructions (2659 KB)

References

[1]. Zhang FL, et al. PLoS One. 2013 Nov 26;8(11):e81815.Topoisomerase I inhibitors, Shikonin and Topotecan, inhibit growth and induce apoptosis of glioma cells andglioma stem cells. [Content Brief]

[2]. Kumar S, et al. Metronomic oral topotecan with pazopanib is an active antiangiogenic regimen in mouse models of aggressive pediatric solid tumor. Clin Cancer Res. 2011 Sep 1;17(17):5656-67. [Content Brief]

Help & FAQs

How should lyophilized recombinant proteins be reconstituted and stored?

1. Before opening the cap, centrifuge the vial at 13000 rpm for 20-30 seconds. This step will ensure that any lyophilized powder that may have adhered to the cap or walls is collected at the bottom of the vial, minimizing the risk of product loss.

Complete Stock Solution Preparation Table

Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month. When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.

Optional Solvent	Concentration Solvent Mass	1 mg	5 mg	10 mg	25 mg
DMSO	1 mM	2.3728 mL	11.8638 mL	23.7276 mL	59.3190 mL
	5 mM	0.4746 mL	2.3728 mL	4.7455 mL	11.8638 mL
	10 mM	0.2373 mL	1.1864 mL	2.3728 mL	5.9319 mL
	15 mM	0.1582 mL	0.7909 mL	1.5818 mL	3.9546 mL
	20 mM	0.1186 mL	0.5932 mL	1.1864 mL	2.9660 mL
	25 mM	0.0949 mL	0.4746 mL	0.9491 mL	2.3728 mL
	30 mM	0.0791 mL	0.3955 mL	0.7909 mL	1.9773 mL
	40 mM	0.0593 mL	0.2966 mL	0.5932 mL	1.4830 mL
	50 mM	0.0475 mL	0.2373 mL	0.4746 mL	1.1864 mL
	60 mM	0.0395 mL	0.1977 mL	0.3955 mL	0.9887 mL
	80 mM	0.0297 mL	0.1483 mL	0.2966 mL	0.7415 mL
	100 mM	0.0237 mL	0.1186 mL	0.2373 mL	0.5932 mL

Keywords

Product Name:
Cat. No.:
Quantity:
MCE Japan Authorized Agent:

Product Name:
CAS No.:
Species:
Purity:
Quantity:

Topotecan

Apoptosis Compound Library

Cell Cycle/DNA Damage Compound Library

FDA-Approved Drug Library

Anti-Cancer Compound Library

Autophagy Compound Library

Anti-Aging Compound Library

Drug Repurposing Compound Library

Anti-diabetic Compound Library

NMPA-Approved Drug Library

Orally Active Compound Library

FDA Approved & Pharmacopeial Drug Library

Anti-Lung Cancer Compound Library

Anti-Pancreatic Cancer Compound Library

Rare Diseases Drug Library

Pediatric Drug Library

Chemotherapy Drug Library

EMA-Approved Drug Library

FDA-Approved Anticancer Drug Library

Human Metabolite Library

Anti-Prostate Cancer Compound Library

Heterocyclic Compound Library

Withdrawn Drug Compound Library

Off-patent Drug Library

Highly Selective Inhibitors Library

Highly Selective Activators Library

Cell Death Library

Anti-Ovarian Cancer Compound Library

Bioactive Compound Library Max

MCE Bioactive Compound Library

Natural Product-like Compound Library

Drug Repurposing Compound Library Plus

FDA-Approved Drug Library Plus

FDA-Approved Drug Library Mini

Natural Product and Natural Product-Like Compound Library

Bioactive Compound Library

Non-Alcoholic Fatty Liver Disease (NAFLD) Compound Library

High-Throughput Bioactive Compound Library

Mass Spectrometry Human Metabolite Library

RNA Binding Bioactive Compound Library

Publications Citing Use of MedChemExpress (MCE) Topotecan

All Topoisomerase Isoforms

Biological Activity

Chemical Information

Publications (38)

Solvent & Solubility

Protocol

Purity & Documentation

References

Help & FAQs

Complete Stock Solution Preparation Table

Topotecan Related Classifications

Cat. No.: HY-13768